WO1991000906A1 - Animaux chimeriques et transgeniques pouvant produire des anticorps humains - Google Patents
Animaux chimeriques et transgeniques pouvant produire des anticorps humains Download PDFInfo
- Publication number
- WO1991000906A1 WO1991000906A1 PCT/US1990/003894 US9003894W WO9100906A1 WO 1991000906 A1 WO1991000906 A1 WO 1991000906A1 US 9003894 W US9003894 W US 9003894W WO 9100906 A1 WO9100906 A1 WO 9100906A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- animal
- human
- immunoglobulin
- fragment
- exogenous
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates generally to immunoglobulin rearrangement in chimeric and transgenic animals, and more specifically to a mouse containing in its germline, and capable of transmitting to its progeny, the ability to generate immunoglobulins characterized by the presence of human heavy chains.
- Immunoglobulins are the proteins which form antibodies.
- the basic unit of an immunoglobulin (Ig) molecule is a complex of two identical heavy (H) and two identical light (L) polypeptide chains. Both types of chains contain a region of variable a ino acid seguence at the amino terminal end (V region) in which reside the primary determinants of antigen binding specificity. Each chain also has a region of constant amino acid sequence (C region) comprising the remainder of the chain, in which reside the primary determinants of the effector functions of the antibody, such as complement fixation and antibody-dependent cellular cytotoxicity.
- variable region of heavy and light chains can be further subdivided into regions of relatively conserved amino acid sequence, framework regions, and regions of highly variable amino acid sequence, hypervariable regions or complementarity determining region ⁇ (CDRs) .
- CDRs complementarity determining region ⁇
- variable regions of both the heavy and light chain genes are assembled from component gene segments.
- the heavy chain variable region gene is assembled from three different elements, variable (V H ) , diversity (D) , and joining (J H ) segments. Families of these segments are encoded in separate clusters along the chromosome. Formation of a functional heavy chain variable region gene involves both joining of a D segment to a J H segment and joining of a V H segment to the pre ⁇ existing DJ K complex to form the complete V H DJ H heavy chain variable region gene.
- V L variable gene segment
- J L joining segment
- kb variable region -several kilobases
- Human or partially human monoclonal antibodies have been obtained by several methods which have proven less than satisfactory for a variety of reasons.
- the production of mouse/human hybridomas has been limited because such lines are unstable genetically and progressively lose human chromosomes. Epstein Barr Virus transformed human B lymphocytes tend to produce small quantities of Ig and are unstable.
- the production of human/human hybridomas has been very limited, due to the lack of a.suitable fusion partner, the lack of sufficient numbers of human B-cells immunized against a desired antigen, poorly defined fusion protocols, and poorly defined culture conditions to support hybrid survival and antibody production.
- such cells predominantly produce antibodies of only the IgM isotype, which is not appropriate for many clinical uses.
- hybridomas Another serious limitation with human hybridomas is the difficulty of growing such cell lines in large quantities, jln vitro culture of such hybridomas is very costly and produces limited quantities of Ig compared to the large amounts that can be obtained from harvesting monoclonal antibodies from murine hybridomas.
- heterologous genes from heterologous species organisms in an animal capable of expressing and regulating the foreign gene construct has been the subject of much recent research.
- U. S. patent 4,736,866 describes a transgenic animal carrying a recombinant activated oncogene sequence; and J. Van Brunt, Biotechnology. (10):1149 (October 1988).
- Buccini et al, Nature, 326:409 (1987) and Goodhardt et al, Proc. Natl. Acad. Sci.. USA, 84 . :4229 (1987) refer to the rearrangement of unarranged chicken and rabbit immunoglobulin gene segments in mice.
- a non-human eukaryotic animal having incorporated into its germline unrearranged DNA fragments bearing exogenous immunoglobulin (Ig) heavy chain gene segments.
- the animal of the invention is capable of rearranging these segments and producing antibodies characterized by the presence of rearranged exogenous Ig heavy chains . ..
- the animal of the invention is also capable of producing an antibody also characterized by the presence of light Ig chains endogenous to said animal.
- the animal of the invention may produce antibody characterized by the presence of exogenous Ig light chains.
- the exogenous gene segments are of human origin.
- Another aspect of this invention is an unrearranged DNA fragment for use in producing the animal of the invention.
- This DNA fragment is composed of at least the following elements: at least one exogenous variable Ig gene segment, at least one exogenous D Ig gene segment, at least one exogenous J Ig gene segment, and at least one ⁇ heavy chain constant Ig region.
- the ⁇ constant region is of exogenous or endogenous species origin,, and is required to mediate allelic exclusion in the animal, of this invention.
- the unrearranged DNA fragment also contains an exogenous gamma constant Ig region.
- the unrearranged DNA fragment of the invention may also contain a switch region of exogenous or endogenous species origin, and exogenous or endogenous species heavy chain enhancers. More preferably the exogenous segments of this unrearranged fragment are of human origin.
- Still another aspect of the present invention is a method for producing the non-human eukaryotic animal of the present invention comprising introducing into the germline of said animal an unrearranged DNA fragment of this invention.
- a further aspect of the present invention is a method for producing the non-human eukaryotic animal of the invention comprising transfecting into a stem cell of the animal a heterologous DNA sequence carrying unrearranged gene segments of exogenous, preferably human, Ig heavy chains. This method may permit introduction into the animal of human DNA of greater than 50kb, if desired.
- Yet another aspect of the invention is a hybridoma cell line and a monoclonal antibody secreted therefrom characterized by the presence of human Ig heavy chains.
- the monoclonal antibody thus produced may further be characterized by the presence of either human or endogenous animal light chains.
- An additional aspect of the invention is a method for producing the hybridoma cell line by use of a cell of an animal of the present invention and a method for obtaining a desired monoclonal antibody of the invention.
- Fig. 1 i-s a graphical illustration of a murine unrearranged DNA fragment according to the present invention.
- Fig. 2 is a graphical illustration of a more complex human unrearranged DNA fragment according to the present invention.
- the present invention provides an animal developed by recombinant genetic engineering techniques which is capable of rearranging in a lymphoid specific manner introduced unrearranged exogenous, preferably human, immunoglobulin genes.
- the animal is thereby capable of producing in vivo resulting B cells which express and use the exogenous Ig polypeptides in a manner identical to the use of its own endogenous Igs produced in the animal's normal B cells.
- the animal of this invention produces in vivo a diversity of mature B lymphocytes, characterized by the presence of exogenous Ig heavy chains.
- the animal is capable of using the rearranged products of the unrearranged DNA fragment, e.g., a functionally rearranged exogenous heavy chain, in an immune response.
- a further characteristic of the animal is an ability to transmit this ability to at least some of its progeny.
- the animals of this invention are designed by the integration into their germlines of DNA carrying unrearranged or only partially rearranged exogenous Ig gene segments.
- the unrearranged DNA fragment carrying the gene segments may be microinjected into the fertilized egg of an animal to develop a transgenic animal or transfected into a stem cell which is used to repopulate an embryo to develop a chimeric animal.
- the human DNA fragments are introduced into a cell of the animal in a manner providing that the introduced DNA is stably maintained in a proportion of those cells and transmitted in the germline of the resulting animal.
- an unrearranged gene fragment of the invention is constructed to carry at a minimum DNA sequences encoding at least one exogenous variable Ig gene segment, at least one D Ig gene segment, at least one exogenous J Ig gene segment, and at least one ⁇ constant Ig region.
- the unrearranged gene fragment further contains an exogenous gamma constant Ig region.
- the ⁇ region may be of exogenous origin or from the animal itself, but is preferably human. This ⁇ region is required to signal appropriate allelic exclusion in the resulting animal.
- the D gene may be of exogenous origin, e.g., human, or from the animal itself. Additionally a synthetic D gene of about 10 to 20 amino acids in length containing flanking sequences from an animal may be employed in the construct of the invention.
- the unrearranged gene fragment of this invention optionally contains multiple copies of the unrearranged or partially rearranged human heavy or light chain variable and constant region gene segments.
- Human gene segments for use in constructing the unrearranged DNA fragment for insertion into a cell of the selected animal of this invention include a D gene which is a short chemically synthesizable fragment.
- D gene region is described in J. V. Ravetch et al, Cell, 22:583 (1981).
- Other useful D regions for the unrearranged DNA fragment of the present invention are described in Y. Ichihara et al, Eur. J. Immunol. , 18:649 (1988) . It is expected that other D regions will eventually be isolated and their sequences determined. These D regions may also form useful components of the unrearranged DNA fragment of the present invention in a manner analogous to the use of the above exemplary D gene segments.
- the D gene need not be of human origin.
- the flanking regions of the D gene may be of one species' origin, which the coding sequence of the D gene may be from another species.
- a synthetic D gene may be made by conventional techniques.
- Presently preferred for use in the construct are any human D or any murine D gene, a variety of which are known in the art, as identified above.
- the J gene regions of the human Ig DNA sequences for use in an unrearranged DNA fragment of the present invention are published. See, e.g. Ravetch et al, cited above; and P. A. Hieter et al, J. Biol. Chem.. 257:1516 (1982).
- the J gene region described by Ravetch, cited above may be obtained requested from the author, based on its publication in the journal, Cell. Additionally, ⁇ and gamma (1 through 4) human gene sequences are published and may be purchased from the Medical Research Council (MRC) in England and employed in the unrearranged DNA fragment. See, e.g., J. W. Ellison et al, Nucl. Acids Res.
- the constant regions may desirably be constructed by employing -conventional recombinant techniques. See, e.g., T. Maniatis et al, Molecular Cloning (A Laboratory - Manual) , Cold Spring Harbor Laboratory (1982) and J.
- Human V gene families I through VI are also published and may be constructed by conventional recombinant techniques for insertion into the unrearranged,DNA fragment of the invention. See, e.g. Berman, J. E. et al, EMBO J. , 2: 27 (1988).
- the DNA sequences of these genes identified above may be synthesized or obtained by conventional recombinant techniques and employed in the unrearranged DNA fragment construct according to the present invention.
- One of skill in the art can obtain members of these gene families by employing conventional cross- hybridization techniques using a representative member of each family.
- the unrearranged DNA fragment's human heavy chain gene segments, V, D, and J, will assemble with animal's own light chains during B lymphocyte maturation to generate antibodies characterized by human heavy chains.
- unrearranged human light chain gene segments may be employed in another unrearranged DNA fragment to enable the resulting animal to produce a diversity of B lymphocytes with both human heavy and light chains.
- the two unrearranged DNA fragments bearing the human heavy chain genes and the human light chain gene, respectively, may be injected into the same animal.
- one animal carrying the first unrearranged DNA fragment may be mated with another animal carrying the second unrearranged DNA fragment to produce progeny capable of using both unrearranged DNA fragments.
- an animal of this invention may be capable of generating antibodies containing human heavy chains and homologous light chains or antibodies characterized by the presence of both human heavy and light chains.
- the unrearranged DNA fragment of the invention may also contain appropriate transcriptional enhancer and promoter elements.
- the animal of the present invention will contain human or homologous animal, e.g., murine, constant region "switch" regions proximal to each constant region.
- the switch regions may also be employed in the design of the unrearranged DNA fragment which is integrated in the animal.
- the switch region is located immediately upstream of the coding regions of the Ig constant genes in the unrearranged DNA fragment.
- Such murine switch regions for use in the unrearranged DNA fragment are also published and may be sequenced or obtained by recombinant technology by one of skill in the art. See, e.g. T.
- Ig heavy chain enhancer sequences useful in the unrearranged DNA fragment of the invention are described in J. Banerji et al, Cell, 3_3_:729 (1983); S. D. Gillies et al, Cell, 3_3:717 (1983); P. Augereau et al, EMBO J.. 5_(8):1791 (1986); and S. Pettersson et al, Nature, 344:165 (1990) and may be obtained by analogous methods.
- the constructed unrearranged DNA fragment may contain human DNA sequences as well as appropriate sequences from other non-human sources, e.g., the animal itself.
- other human heavy and light chain gene segments or other non-human sequences such as the switch regions, suitable promoters or enhancers, when their sequences are known, will also be useful to form unrearranged DNA fragments according to the teachings of the present invention and may be used in analogous manner to the exemplary sequences described herein.
- the gene segments useful in the unrearranged DNA fragments may be obtained by preparing lambda phage genomic and cDNA libraries and identifying specific Ig genes according to known techniques. See, T. Maniatis et al and Sambrook et al, cited above.
- the unrearranged DNA fragment of this invention may vary considerably in size and is preferably approximately 25 to 50 kb in length for ease of manipulation in cosmids. Larger DNA fragments of human origin may be used for construction of a chimeric animal or transgenic animal and will be propagated in yeast artificial chromosome vectors (YACS) .
- YACS yeast artificial chromosome vectors
- animals of the invention may be produced alternatively by isolating a contiguous human DNA fragment carrying naturally unrearranged DNA sequences encoding multiple human Ig heavy chain segments, e.g., V H , D and J H .
- V H , D and J H multiple human Ig heavy chain segments
- These naturally unrearranged fragments may be considerably larger in size than the ⁇ ni-jearranged DNA fragment constructs described above and may require propagation in YACS vectors.
- An example of such a contiguous DNA fragment that could be isolated, in this way is described by Berman, J. E. et al, EMBQ J. , 2:727 (1988). This fragment is of 85-100 kb containing a human V gene segment, multiple human D segments, and the complete human J H - C ⁇ region.
- the constructed unrearranged DNA fragments may be propagated in conventional plasmids or cosmids known to those of skill in the art.
- conventional vectors useful for transgene replication are the cosmid vectors p E15 or pWE16, supplied commercially by Stratagene, La Jolla, California.
- the larger chromosomal DNA sequences may be propagated in conventional yeast artificial chromosome vectors in yeast as described in D. T. Burke, et al, Science, 236:806 (1987).
- the animal of the invention is developed by introducing into a cell of the animal this human DNA. This introduction is performed so that the introduced DNA is stably maintained and transmitted in the germline of the animal.
- Expression of functional Ig genes depends on an accurate rearrangement of DNA in the cells of the animal to bring the several gene segments e.g. variable, diversity, and joining for the heavy chain and variable and joining for the light chain, into juxtaposition.
- the mechanism of allelic exclusion operates to prevent further rearrangement in a second chromosome once a complete functional unit is achieved in one chromosome.
- the unrearranged or partially rearranged gene segments in the fragment allow for maximum diversity to be generated in the animal through the use of alternative V H , D and J H genes, and the generation of junctional diversity. Additionally the utilization of unrearranged genes is expected to lead to a more physiological response than programming an animal with completely assembled Ig genes.
- Transgenic animals can be produced by several standard procedures, the most common being microinjection of the cloned unrearranged DNA fragment into one of the pronuclei of a fertilized egg according to the procedure described in R. Brinster et al, PNAS USA, j32.:4438 (1985). See also, Cqnstantini et al, J. Cell. Phvsiol.. Suppl.:219-226 (1982) ; E. Robertson et al, Nature. 323:445 (1986) ; M. R. Kuehn et al, Nature, .32_6:295 (1987); M. Hooper et al, Nature, 326:292 (1987); and B.
- the microinjected embryos are developed to term in the uterus of a pseudo pregnant animal. As many as 25% of the resulting progeny can contain the injected unrearranged DNA fragment.
- This procedure introduces the cloned human Ig genes into every cell of the resulting transgenic animal. Such introduced Ig genes are expressed almost exclusively in the same tissues in which the homologous endogenous genes are expressed.
- the animals containing the unrearranged DNA fragments generally contain the foreign DNA stably integrated in all cells. This DNA is thereafter propagated in the germline.
- a naturally unrearranged human DNA fragment as described above, can be introduced into isolated embryonal stem cells of the animal to create chimeric animals.
- Cells which have integrated the human DNA are grown in culture, and can be used to repopulate animal embryos. Such cells could be selected for those bearing the human DNA by the polymerase chain reaction, with appropriate primers [See, e.g., R. K. Saiki, et al, Science, 239:487 (1988).
- a drug resistance gene e.g., neo, may be linked to the introduced DNA and the cells selected for growth in the presence of the drug.
- the resulting chimeric animal contains a population of cells, some of which descend from the altered pluripotent stem cell which carry the human DNA.
- transgenic animal can then be derived from such a chimeric animal by breeding.
- Such techniques for obtaining chimeric and transgenic animals are described in K. R. Thomas et al, Cell, 5.1:503 (1987); E. Robertson et al, Nature, 323:445 (1986); M. Hooper et al, Nature, 326:292 (1987) and M. R. Kuehn et al, Nature, 326:295 (1987) .
- the resulting animal of the invention is thus a chimeric or transgenic non-human eukaryotic animal having incorporated into its germline unrearranged DNA fragments bearing human immunoglobulin gene segments.
- the animal of the invention is capable of rearranging the human Ig gene segments to form human or partially human antibodies characterized by human heavy chains, which can be used in an immune response to an exogenous antigen.
- the invention provides a genetically engineered chimeric or transgenic animal capable of producing a Adversity of antibodies characterized by the presence of human heavy chains.
- a chimeric animal is an animal which derives a specific subset of its cells from a single particular pluripotent stem cell which is introduced into the embryo of a normal animal. That stem cell and its progeny can be distinguished from other cells of the resulting animal, for example, by containing specific DNA sequences which were present in the introduced stem cell and not in the other stem cells that eventually develop to produce the animal.
- a chimeric animal according to this invention will have a population of cells that contain the heterologous DNA fragment containing unrearranged or partially unrearranged sequences for the heterologous Ig heavy chain genes and a population of cells which do not contain the introduced DNA.
- the original chimeric animal will have only a certain percentage of its progeny bearing and expressing the foreign DNA.
- Selective breeding of chimeric animals according to techniques known to one of skill in the art can eventually produce a transgenic animal.
- a transgenic animal is an animal that carries specifically introduced heterologous DNA, such as an unrearranged DNA fragment of this invention, integrated into its genome so that the introduced sequence is present in every cell of the animal. A transgenic animal is therefore able to transmit the heterologous DNA sequence to some or all of its progeny.
- the original transgenic animal is heterozygous with respect to the foreign DNA, only some of its progeny will inherit the foreign DNA-from it. If the original heterozygous transgenic animal is mated with a normal animal, the progeny will either be heterozygous or non-transgenic. If the transgenic animal is mated with another heterozygous transgenic animal, some of the progeny will be heterozygous, some will not inherit the foreign DNA at all, and some will be homozygous. The homozygous transgenic animal when mated with other homozygous transgenic animals will always produce homozygous transgenic animals carrying the foreign DNA.
- all animals whether chimeric, or homozygous transgenic or heterozygous.transgenic for the human DNA, will express some level of antibody characterized by the presence of human Ig heavy chains. All such animals capable of producing antibody characterized by the presence of human Ig heavy chains at any level are encompassed by the present invention.
- any non-human eukaryotic animal may be employed in the present invention, preferably the animals will be conventionally used laboratory animals, such as rodents. More particularly, the animals of the invention are anticipated to be laboratory strains of mice. Any animal carrying the unrearranged DNA fragment of the invention may generate a mixture of its homologous antibodies as well as antibodies characterized by human Ig heavy chains. Natural antigen-independent antibody developmental processes cause the animal to produce mature B lymphocytes to circulate in the transgenic or chimeric animal.
- the animal's serum or tissue may be examined using commercially available anti-human Ig antisera in an enzyme-linked immunosorbent assay (ELISA) [See, e.g., Voller A. et al, "The Enzyme Linked Immunosorbent Assay", Dynatech Europe, Under House, Guernsey UK (1979) and Bos, E. S. et al, J. Immunoassay, 2.:187 ' (1981) ] .
- ELISA enzyme-linked immunosorbent assay
- the tail DNA is prepared and probed in a Southern blot by using a portion of the unrearranged DNA fragment as a probe.
- the spleen of the animal is removed by conventional splenectomy (spleen cells contain predominantly B lymphocytes) and the tissue examined on a Southern blot for hybridization and rearrangement.
- An alternative method of detecting appropriate Ig rearrangement is to prepare RNA from central (fetal liver and bone marrow) and peripheral (spleen) lymphoid organs and assay for expression of the rearranged DNA in the fragment via Northern blot analyses with probes specific for human V H and C regions.
- strains of transgenic or chimeric animals containing different human Ig genes are mated, by standard breeding techniques, and progeny selected that contain multiple different human Ig transgenes. Such progeny are identified by the procedures described above.
- Hybridoma cell lines secreting monoclonal antibodies directed to a particular antigenic epitope may be developed from the chimeric or transgenic animals of the present invention.
- the animal is immunized with a selected antigen, for example, a tumor antigen (to generate an anti-tumor antibody), an antibody to an infectious agent, e g., a bacterium or ** •mvirus, e.g., HIV, or other antigenic substance of choice.
- the mature B lymphocytes in the animals of the invention then generate a specific antibody response to the antigen.
- Such an antibody response would include heavy chains expressed from the foreign DNA fragments, now rearranged.
- the unrearranged DNA fragments in the animals have functionally rearranged to produce a human Ig heavy chain and/or Ig light chain, during the pre-B cell stage, the remainder of the differentiation of the B cells is normal.
- Spleen B cells are isolated from the animals after primary or secondary immunization. Traditional Kohler and Milstein techniques are employed and the splenic B lymphocytes fused with a selected myeloma cell line.
- hybridoma cell line which when cultured in appropriate culture medium and under suitable conditions known to those of skill in the art secretes a selected monoclonal antibody.
- the development of a hybridoma cell line according to this invention is not limited to the selection of specific myeloma cell lines or antigens. These hybridoma cell lines are screened by standard techniques for the production of anti-specific antigen antibodies. Hybridomas which use the transgenic heavy chain genes to produce antibody are identifiable by use of a transgene specific probe. Exemplary probes are antisera against the human Ig constant regions.
- the transgene construct may also incorporate a
- DHFR or other selectable and/or amplifiable marker.
- This marker gene may be linked with an independent promoter element, such as DHFR cDNA linked to an SV40 promoter and polyadenylation sequences.
- DHRF cDNA may be placed immediately downstream of an encephalomyelocarditis virus or polio virus leader 26 sequence without an independent promoter element [See, e.g., J. Pelletier et al, Nature, 334:320 (1988); S. K. Jang et al, J. Virol. , .63..-1651 (1989)].
- This latter structure may be placed immediately downstream of the coding sequence of the secreted exon terminus for the heavy chain constant region, upstream of necessary polyA addition sequences. This ensures the presence and expression of the DHFR message that is expected in,resulting hybridomas expressing the Ig transgene. If the structure is attached in this manner to the gamma constant region in a construct similar to that of Example 2 with ⁇ and gamma constant regions, selection for expresion of DHFR by conventional means would allow selection of cells that have class switched from transgene ⁇ to gamma expression. In either strategy, the presence of the marker gene would allow selection for the maintenance of the chromosome bearing the transgene and may amplify transgene sequences.
- Monoclonal antibodies characterized by the presence of human Ig heavy chains have great potential therapeutic use in the treatment of a variety of human disorders amenable to antibody treatment.
- the presence of the human heavy chains in these antibodies are likely to be considerably less provocative of an anaphylactic response in a human patient than antibodies characterized by the presence of non-human heavy chains.
- Monoclonal antibodies have immense potential for use as prophylactic, diagnostic, and therapeutic agents in the treatment of various types of human ailments. Potential or actual applications of these reagents include the provision of passive immunity against various microorganisms and viruses when injected into human patients.
- these antibodies may be employed in the neutralization of viruses, parasites, and bacteria, for example, bacterial toxins or snake venoms.
- the antibodies may also be used to neutralize pharmaceutical drugs with low toxicity thresholds, such as digoxin, or in treating drug overdoses. Additionally such antibodies may neutralize B lineage cells producing autoimmune antibodies or T lineage cells producing cell- mediated self-destructive responses. Among other conditions which can be neutralized by use of these antibodies are allergic responses. Significantly, the neutralization of tumor cells is another important area of therapy for the antibodies of this invention. These antibodies may also be employed in mediating normal antibody functions.
- An unrearranged DNA fragment construct according to this invention is called pV ⁇ [See Fig. 1A] . It contains the murine germline V 186 . 2 segment [Bothwell, A.L.M. et al, Cell. 2_4:625 (1981)], which is known to be used in the antibody response to 4-hydroxy-3-nitrophenyl (NP) .
- a panel of hybridomas are generated from the transgenic mice containing this construct, immunized with the NP-hapten conjugated to keyhole limpet hemocyanin.
- This V segment is upstream of a D Q52 -J H 2 rearrangement / with unrearranged J H 3 and J H 4 segments and the heavy chain enhancer downstream.
- This D Q52 -J H 2 rearrangement is generated by recombination of these sequences after transfection into the Abelson murine leukemia virus-transformed pre-B cell line, 38B9 [Blackwell, T.K. and Alt, F. W. , Cell. 37:105 (1984)].
- the nucleotide sequence of this DJ H join, called 112-2 has been determined [Blackwell, T. K. et al, Nature, 324:585 (1986].
- the "spacer" between the 3' end of the V 186 has been determined [Blackwell, T. K. et al, Nature, 324:585 (1986].
- the D JH 2 segment is comprised of approximately 3.5 kb of sequence derived from the V 186 .
- Downstream of the heavy chain enhancer is the coding sequences for the murine ⁇ constant region, derived from a genomic clone, called p ⁇ 5 [Alt, F. . et al, Cell. 22:381 (1981)].
- This clone contains an approximately 10.5 kb Eco RI fragment bearing the ⁇ coding region. The entire Eco RI fragment is incorporated into pV ⁇ .
- This construct is designed with the intention of excising the V 186 . 2 -DJ H - ⁇ region on a single Not I fragment of approximately 22 kb, that can be purified for microinjection.
- a DNA fragment construct contains no vector DNA that could potentially interfere with the rearrangement or expression of the immunoglobulin gene.
- the cos id construct, pV ⁇ is prepared as follows: i) The 10.5 kb genomic ⁇ fragment is cloned into a derivative of pSP65, called pSP65N, having a unique Not I site. Another plasmid for this use is the Bluescript plasmid [Stratagene, La Jolla, CA] .
- Plasmid pSP65N is prepared from pSP65 [Promega Biotec, Madison, WI] by destroying the unique Hindlll site, and replacing it with a unique Not I site using synthetic oligodeoxy ribonucleotides.
- the genomic ⁇ fragment is an Eco RI fragment, and therefore, can be cloned into Eco RI- digested pSP65N.
- appropriate restriction enzymes that cleave within the ⁇ sequence such as Bgl II and Xho I, a clone can be selected that has the 3' end of the fragment. This plasmid is called pSP65N ⁇ .
- V 186.2 and D Jf) 2 segments are on Eco RI fragments of approximately 7 kb and 4 kb, respectively.
- the Eco RI fragment bearing V 186.2 is cloned into the Eco RI site of pSP65N, and a clone selected that has the Not I site of the plasmid at the 5' end of the V 186 . 2 coding region.
- the Eco RI site proximal to the Not I site is destroyed, by carrying out a partial Eco RI digestion, purifying the single cut DNA from a low melt agarose gel, digesting with T4 DNA polymerase in the presence of all of the four different deoxynucleoside triphosphates, and religating.
- pSP65NV is digested with Eco RI, and the Eco RI fragment bearing the DJ H 2 segment is ligated into this site.
- a resultant clone is selected that has the V and DJ H 2 segments in the correct orientation.
- Such a clone has a Xho I site immediately upstream of the DJ H 2, and 2.4 kb from the 3' Eco RI site.
- the internal Eco RI site of this clone is destroyed, by a similar procedure to that used in (ii) above.
- pSP65NVDJ has a Not I-Eco RI fragment of approximately 11 kb.
- pV ⁇ is constructed by ligating the 11 kb Not I-Eco RI fragment of pSP65NVDJ with the 10.5 kb Eco RI-Not I ⁇ fragment generated by complete Not I - partial Eco RI digest of pSP65N ⁇ , in the presence of a Not I - digested cosmid vector.
- a derivative of the cosmid vector p E15 [Stratagene, La Jolla] is used in the construction of this unrearranged DNA fragment construct in which the SV40 promoter-neo gene cassette has been replaced by a mutant dihydrofolate reductase (DHFR) gene.
- DHFR dihydrofolate reductase
- This gene is useful as a dominant selectable marker.
- This gene is incorporated into the DNA construct flanking the Ig gene segments, and is used for co-amplifying and increasing the expression of the rearranged DNA in resultant hybridomas from the transgenic animal.
- An example of the use of a mutant DHFR gene to amplify the expression of linked DNA sequences is provided by H. Dora et al, J. Immunol., 139:4232 (1987).
- This ligation is carried out under standard conditions for cosmid ligations.
- the ligation products are incubated with jLn vitro bacteriophage lambda packaging extracts, and then used to infect __)___ coli HB101.
- the resultant colonies are screened by restriction enzyme digestion analysis, and in situ hybridization to the different fragments that make up the desired construct.
- Another unrearranged DNA fragment construct according to this invention comprises an unrearranged human V H gene segment, the human J H locus with a single upstream, unrearranged D segment, the murine ⁇ gene including its upstream ⁇ switch region, the murine gamma 2b switch region, and the human gamma 1 coding region.
- the murine ⁇ may be changed for the human ⁇ region, since both regions have been found to signal allelic exclusion in transgenic mouse models.
- Human switch regions may also be substituted for switch regions of murine origin, i) The human 1-9II V H gene segment of the V H 4 family described in Berman, J. E. et al, EMBO J.
- J H fragment also includes one unrearranged D segment [J. V. Ravetch et al, Cell, 22:583 (1981)].
- a clone, called pSP65NHVJ, is selected in which the J H locus is in the correct orientation to the V H segment, placing the D segment between the V H and J H segments.
- pSP65NHVJ The murine germline ⁇ gene found on plasmid p ⁇ [Grosschedl et al, Cell, .38.:647 (1984)], is excised therefrom on an approximately 10.5 kb Eco Rl-Xho I fragment. This fragment is cloned into the Bluescript plasmid digested with Eco RI and Xho I. The resulting clone is then digested with Xho I, which cleaves in the vector polylinker.
- the cleaved DNA is treated with T4 DNA polymerase in the presence of all four deoxynucleoside triphosphates, and then ligated with synthetic DNA linkers containing an Sfi I site.
- the DNA is then digested with Sfi I and religated.
- the resulting plasmid, p ⁇ Sfi I contains an approximately 10.5 kb genomic fragment, with a unique Eco RI site at the 5' end, and a unique Sfi I site at the 3' end.
- the murine gamma 2b switch region is excised from the genomic clone SL1 in a bacteriophage lambda vector, on an Eco RI-Hindlll fragment of approximately 4.4 kb [See, e.g., Stanton and Marcu, Nucl. Acids Res. , JL0 . :5993 (1982)].
- This DNA is cloned into the Eco RI and flindlll sites of the Bluescript plasmid.
- the 5* vector Not I site is then destroyed, and replaced with the same synthetic Sfi I linkers, as described in (ii) .
- the 3' vector Sal I site is destroyed, and synthetic Not I linkers are used to create a new Not I site.
- the resulting clone is called pBS gamma 2b.
- the human gamma l gene is excised from the clone HG3 on a Hindlll fragment [Ellison, J. . et al, Nucleic Acids Res.. 10:4071 (1982)]. This Hindlll fragment is cloned into the Hindlll site of pBS gamma 2b.
- a recombinant clone, called pBS gamma 1 is selected that has the gamma 1 gene in the correct orientation, with respect to the gamma 2b switch region.
- the same or similar gamma 1 fragments may be obtained from other genomic human gamma 1 clones, if desired.
- the following fragments are then prepared: (1) a Not I-partial Eco RI V H -D-J H fragment of pSP65NHVJ (2 kb) ; (2) an Eco Rl-Sfi I ⁇ fragment of p ⁇ Sfi I (10.5 kb) ; and (3) a Sfi I-Not I Sgamma 2b-human gamma 1 fragment of pBS gamma 1.
- These fragments are then ligated with a Not I digested cosmid vector, under standard cosmid ligation conditions, as in Example 1.
- Clones are identified that contain a V-D-J H - ⁇ -S gamma2b-gamma 1 unrearranged DNA fragment construct. Such a construct is excised from the clone by Not I digestion, and purified for microinjection.
- Example 3 Production of a Transgenic Mouse
- the unrearranged DNA fragment constructs described in Examples 1 and 2 are employed to produce transgenic mice, as follows:
- mice were obtained essentially as described by B. Hogan et al, "Manipulating the Mouse Embryo, A Laboratory Manual", Cold Spring Harbor
- mice are transgenic, according to the invention.
- Sail-EcoRI double digestion of the unrearranged DNA fragment construct should generate an llkb fragment containing V186-2 and DJ H 2. Rearrangement of these two gene segments and deletion of the spacer DNA is predicted to generate a Sall-EcoRI fragment of approximately 4kb.
- tail DNA of 1763 is found to have an unrearranged band of llkb, and the endogenous _T H band of approximately 6.2kb.
- a 4kb band is found, indicating rearrangement of the DNA fragment in the spleen but not the tail tissue of the animal.
- the remaining spleen DNA preparation of mouse 1763 is digested with Sail and EcoRI, and the DNA in the 3.5-4.5kb size range is eluted from a preparative agarose gel.
- This DNA is cloned into the bacteriophage lambda vector, lambda ZAP [Stratagene] .
- the resulting plaques are screened with a J H probe and picked.
- the inserts are converted to plas ids using the lambda ZAP excision method. These plasmids are rescreened with the same probe, and positive colonies isolated.
- the nucleotide sequence of each insert is then determined using synthetic oligonucleotides to prime chain synthesis. Two oligonucleotides are employed, one hybridizing to the 3' end of J H 2, and the other hybridizing to the 5' end of V 186.2 .
- the nucleotide sequence of four of the DNA fragment rearrangements from spleen DNA are determined from the ATG initiation codon of V 186 . 2 to the 3 ' end of the DJ R 2 segment. From the sequence of the V H -to-DJ H joins of the first four rearranged V region sequences, the DNA fragments are observed to be rearranged with junctional variation occurring. These rearranged V H -DJ dock joins appear indistinguishable from those expected for endogenous gene segments. In two of the four sequences, there is a loss of one or more base pairs from the 3' end of V 186 . 2 . In all four sequences, there is a loss of two or more base- pairs from the 5' sequence of the DJ H segment.
- N-regions are inserted between the recombined V and DJ H segments of one or three base- pairs.
- this sample of junction sequences is small, there appears to be a preference for G-C base- pairs in the N-regions.
- This observation is consistent with the known nucleotide preference of terminal deoxynucleotidyl transferase, which has been implicated in adding the extra bases of the N-region to such junctions. [See, e.g., F. W. Alt et al, Proc. Natl. Acad. Sci. USA, 29:4118 (1982) and Kurosawa et al, J. Exp. Med.. 155:201 (1982)].
- sequences of the rearranged DNA fragment V regions are identical, outside the region of the V H -to DJ H join, and identical to the known sequences of V 186 _ 2 and J H 2.
- no somatic mutation occurs in the sequenced rearranged DNA constructs, a result that would be expected from the analysis of rearrangements in total spleen DNA.
- Numerous modifications and variations in practice of this invention are expected to occur to those skilled in the art. For example, as more human immunoglobulin gene sequences are identified, one of skill in the art can easily apply the teaching of the this invention to construct appropriate transgenes for the preparation of a transgenic animal capable of expressing an antibody characterized by the presence of that particular immunoglobulin. Such modifications therefore are believed to fall within the scope of this invention.
Abstract
Cette invention prévoit un animal eucaryotique non humain et chimérique ou transgénique possédant des fragments d'ADN sans réarrangement incorporés à sa ligne de germes, lesdits fragments portant des segments exogènes de gènes d'immunoglobuline. Cet animal peut réarranger ces segments et produire des anticorps caractérisés par la présence de chaînes lourdes Ig d'espèces exogènes réarrangées.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37894489A | 1989-07-12 | 1989-07-12 | |
US378,944 | 1989-07-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991000906A1 true WO1991000906A1 (fr) | 1991-01-24 |
Family
ID=23495178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/003894 WO1991000906A1 (fr) | 1989-07-12 | 1990-07-11 | Animaux chimeriques et transgeniques pouvant produire des anticorps humains |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1991000906A1 (fr) |
Cited By (217)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0546073A1 (fr) * | 1990-08-29 | 1993-06-16 | Genpharm Int | Animaux non humains transgeniques capables de produire des anticorps heterologues. |
WO1994025585A1 (fr) * | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Animaux transgeniques capables de produire des anticorps heterologues |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1996034096A1 (fr) * | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Anticorps humains derives de xeno-souris immunisees |
EP0746609A1 (fr) * | 1991-12-17 | 1996-12-11 | Genpharm International | Animaux transgeniques non humains capables de produire des anticorps heterologues |
WO1997013852A1 (fr) * | 1995-10-10 | 1997-04-17 | Genpharm International, Inc. | Animaux non humains transgeniques pouvant produire des anticorps heterologues |
US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1998024893A2 (fr) * | 1996-12-03 | 1998-06-11 | Abgenix, Inc. | MAMMIFERES TRANSGENIQUES POSSEDANT DES LOCI DE GENES D'IMMUNOGLOBULINE D'ORIGINE HUMAINE, DOTES DE REGIONS VH ET Vλ, ET ANTICORPS PRODUITS A PARTIR DE TELS MAMMIFERES |
US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) * | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) * | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) * | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP0939763A1 (fr) * | 1996-03-20 | 1999-09-08 | Abgenix, Inc. | Recombinaison dirigee de l'adn a mediation par transition |
US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
AU743883B2 (en) * | 1991-12-17 | 2002-02-07 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
AU781922B2 (en) * | 1991-12-17 | 2005-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
EP1798240A1 (fr) | 2005-12-15 | 2007-06-20 | Industrial Technology Research Institute | Polypeptides recombinants à structure en triple helice |
US7282568B2 (en) | 2002-12-16 | 2007-10-16 | Medarex, Inc. | Human monoclonal antibodies against interleukin 8 (IL-8) |
WO2008060776A2 (fr) | 2006-10-03 | 2008-05-22 | University Of Medicine And Dentistry Of New Jersey | Peptides atap, acides nucléiques le codant et procédés d'utilisation correspondants |
EP1958966A2 (fr) | 1994-07-01 | 2008-08-20 | Dana-Farber Cancer Institute | Procédé pour moduler des réponses de lymphocytes T en manipulant une chaîne gamma de récepteur de cytokine courante |
EP2065402A1 (fr) | 2007-11-30 | 2009-06-03 | Industrial Technology Research Institut | Anticorps de base de collagène trimérique |
WO2009086003A1 (fr) | 2007-12-20 | 2009-07-09 | Xoma Technology Ltd. | Procédés pour le traitement de la goutte |
US7704503B2 (en) | 2005-02-14 | 2010-04-27 | Wyeth Llc | Use of IL-17F in diagnosis and therapy of airway inflammation |
WO2010069331A2 (fr) | 2008-12-19 | 2010-06-24 | H. Lundbeck A/S | Modulation de la famille de récepteurs à domaine vps10p pour le traitement de troubles mentaux et comportementaux |
US7745391B2 (en) | 2001-09-14 | 2010-06-29 | Compugen Ltd. | Human thrombospondin polypeptide |
WO2010075475A1 (fr) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anticorps tyrosine kinase du type fms soluble (sflt-1) et composition associée, trousse, procédés d'utilisation, matériaux et procédé de fabrication |
US7807798B2 (en) | 1997-05-05 | 2010-10-05 | Amgen Fremont Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO2010112034A2 (fr) | 2009-04-02 | 2010-10-07 | Aarhus Universitet | Compositions et méthodes pour le traitement et le diagnostic de synucléinopathies |
EP2251026A1 (fr) | 2000-06-08 | 2010-11-17 | Immune Disease Institute, Inc. | Procédés et compositions pour l'inhibition de lésions de reperfusion à médiation par immunoglobulines |
EP2264163A2 (fr) | 2001-02-16 | 2010-12-22 | Regeneron Pharmaceuticals, Inc. | Procédés de modification de cellules eucaryotes |
EP2277542A1 (fr) | 2001-06-01 | 2011-01-26 | Cornell Research Foundation Inc. | Anticorps modifiés dirigés contre l'antigène prostatique spécifique membranaire et utilisations associées |
EP2290077A2 (fr) | 2004-03-01 | 2011-03-02 | Immune Disease Institute, Inc. | Anticorps naturels IgM et leur inhibiteurs |
US7910798B2 (en) | 2006-03-31 | 2011-03-22 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
WO2011038301A2 (fr) | 2009-09-25 | 2011-03-31 | Xoma Technology Ltd. | Procédés de criblage |
WO2011038302A2 (fr) | 2009-09-25 | 2011-03-31 | Xoma Technology Ltd. | Nouveaux modulateurs |
WO2011116023A1 (fr) | 2010-03-18 | 2011-09-22 | Abbott Laboratories | Procédé permettant d'analyser la lipocaline urinaire associée à la gélatinase des polynucléaires neutrophiles (ungal) dans le pronostic de la fonction de transplantation rénale cadavérique chez un patient, y compris un patient chez lequel a été diagnostiquée une reprise retardée de la fonction du greffon (dgf), procédé permettant d'analyser la ungal dans l'évaluation du risque de dgf chez un patient chez lequel a été diagnostiquée une reprise avancée de la fonction du greffon (egf), et kits afférents |
WO2011119484A1 (fr) | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Procédés bioinformatiques pour déterminer la liaison de peptides |
EP2386318A1 (fr) | 2003-05-15 | 2011-11-16 | Iogenetics, Inc. | Biocides ciblés |
WO2011163558A1 (fr) | 2010-06-25 | 2011-12-29 | Abbott Laboratories | Matériaux et procédés pour le dosage d'anticorps anti-virus de l'hépatite c (hvc) |
WO2012010321A1 (fr) | 2010-07-23 | 2012-01-26 | Erasmus University Medical Center Rotterdam | Inhibiteur de l'hémoglobine fœtale |
WO2012010855A1 (fr) | 2010-07-23 | 2012-01-26 | Medical Research Council | Immunité intracellulaire |
EP2436695A1 (fr) | 2005-04-14 | 2012-04-04 | Wyeth LLC | Méthodes de traitement et de prévention de la fibrose par des antagonistes de l'IL-21/IL-21R |
AU2008200005B2 (en) * | 1996-12-03 | 2012-05-17 | Amgen Fremont Inc. | Transgenic Mammals Having Human Ig Loci Including Plural Vh and Vk Regions and Antibodies Produced Therefrom |
WO2012064674A1 (fr) | 2010-11-09 | 2012-05-18 | Abbott Laboratories | Matériels et méthodes pour un immunoessai permettant d'analyser les ptérines |
EP2471809A1 (fr) | 2006-07-11 | 2012-07-04 | University Of Medicine And Dentistry Of New Jersey | Protéines, acides nucléiques codant pour celles-ci et procédés d'utilisation correspondants |
EP2478918A2 (fr) | 2005-11-10 | 2012-07-25 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions et procédés pour le traitement de l'addiction et autres troubles neuropsychiatriques |
US8278421B2 (en) | 2006-03-20 | 2012-10-02 | Xoma Techolology Ltd. | Human antibodies specific for gastrin materials and methods |
EP2508608A1 (fr) | 2003-06-09 | 2012-10-10 | Alnylam Pharmaceuticals Inc. | Procédé de traitement d'une maladie neurodégénérative |
WO2012167143A1 (fr) | 2011-06-03 | 2012-12-06 | Xoma Technology Ltd. | Anticorps spécifiques du tgf bêta |
WO2013040142A2 (fr) | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Procédés bio-informatiques de détermination de liaisons peptidiques |
WO2013096516A1 (fr) | 2011-12-19 | 2013-06-27 | Xoma Technology Ltd. | Méthodes de traitement de l'acné |
WO2013102149A1 (fr) | 2011-12-31 | 2013-07-04 | Abbott Laboratories | Protéine de liaison de la vitamine d humaine tronquée et mutation et fusion de celle-ci, et matériaux associés et procédés d'utilisation |
WO2013117735A1 (fr) | 2012-02-09 | 2013-08-15 | Medical Research Council | Conjugué comprenant un agent et un ligand antiviral, et son utilisation dans un procédé d'administration de l'agent par voie intracellulaire |
WO2013144567A1 (fr) | 2012-03-28 | 2013-10-03 | Kymab Limited | Vertébré non-humain transgénique pour l'expression d'anticorps entièrement humains à commutation isotypique |
US8653020B2 (en) | 2008-01-25 | 2014-02-18 | Aarhus Universitet | Selective exosite inhibition of PAPP-A activity against IGFBP-4 |
WO2014058875A2 (fr) | 2012-10-09 | 2014-04-17 | Biogen Idec Ma Inc. | Polythérapies et leurs utilisations pour le traitement de troubles de la démyélinisation |
EP2732823A1 (fr) | 2008-06-25 | 2014-05-21 | H. Lundbeck A/S | Modulation de la trpV : Système de récepteur du domaine vps10p pour le traitement de la douleur |
US8759105B2 (en) | 2000-10-31 | 2014-06-24 | Regeneron Pharmaceuticals, Inc. | Method for genetically modifying mouse embryonic stem cell by homologous recombination |
US9078886B2 (en) | 2010-06-16 | 2015-07-14 | Embera Neurotherapeutics, Inc. | Compositions for the treatment of addiction, psychiatric disorders, and neurodegenerative disease |
WO2015122995A1 (fr) | 2014-02-11 | 2015-08-20 | Visterra, Inc. | Molécules d'anticorps se liant au virus de la dengue et leurs utilisations |
EP2501817B1 (fr) | 2010-02-08 | 2015-08-26 | Regeneron Pharmaceuticals, Inc. | Souris à chaîne légère commune |
WO2015138920A1 (fr) | 2014-03-14 | 2015-09-17 | Novartis Ag | Molécules d'anticorps anti-lag-3 et leurs utilisations |
EP2701499B1 (fr) | 2011-04-25 | 2016-02-10 | Regeneron Pharmaceuticals, Inc. | Animaux non humains exprimant des anticorps possédant une chaîne légère commune |
WO2016040880A1 (fr) | 2014-09-13 | 2016-03-17 | Novartis Ag | Thérapies combinées d'inhibiteurs d'alk |
WO2016054555A2 (fr) | 2014-10-03 | 2016-04-07 | Novartis Ag | Polythérapies |
US9309315B2 (en) | 2005-08-18 | 2016-04-12 | Genmab A/S | Therapy with CD4 binding peptides and radiation |
WO2016061142A1 (fr) | 2014-10-14 | 2016-04-21 | Novartis Ag | Molécules d'anticorps de pd-l1 et leurs utilisations |
US9346873B2 (en) | 2008-09-30 | 2016-05-24 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
WO2016100882A1 (fr) | 2014-12-19 | 2016-06-23 | Novartis Ag | Polythérapies |
US9434782B2 (en) | 2009-07-08 | 2016-09-06 | Kymab Limited | Animal models and therapeutic molecules |
WO2016141111A1 (fr) | 2015-03-03 | 2016-09-09 | Xoma (Us) Llc | Traitement d'une hyperinsulinémie post-prandiale et d'une hypoglycémie après chirurgie bariatrique |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
WO2016161410A2 (fr) | 2015-04-03 | 2016-10-06 | Xoma Technology Ltd. | Traitement du cancer à l'aide d'inhibiteurs de tgf-bêta et pd-1 |
US9499838B2 (en) | 2001-05-11 | 2016-11-22 | Kyowa Hakko Kirin Co., Ltd. | Human artificial chromosome containing human antibody λ light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission |
EP3124045A2 (fr) | 2006-12-20 | 2017-02-01 | Xoma (Us) Llc | Traitement de maladies apparentées il-1 beta |
WO2017019897A1 (fr) | 2015-07-29 | 2017-02-02 | Novartis Ag | Polythérapies comprenant des molécules d'anticorps contre tim -3 |
WO2017019894A1 (fr) | 2015-07-29 | 2017-02-02 | Novartis Ag | Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3 |
US9580491B2 (en) | 2010-03-31 | 2017-02-28 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US9622459B2 (en) | 2011-12-20 | 2017-04-18 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
WO2017083515A2 (fr) | 2015-11-10 | 2017-05-18 | Visterra, Inc. | Conjugués molécules anticorps-médicaments et leurs utilisations |
WO2017091683A1 (fr) | 2015-11-25 | 2017-06-01 | Visterra, Inc. | Molécules d'anticorps se liant à april et leurs utilisations |
WO2017106810A2 (fr) | 2015-12-17 | 2017-06-22 | Novartis Ag | Combinaison d'un inhibiteur de c-met avec une molécule d'anticorps dirigée contre pd-1 et ses utilisations |
WO2017106656A1 (fr) | 2015-12-17 | 2017-06-22 | Novartis Ag | Molécules d'anticorps anti-pd-1 et leurs utilisations |
US9686970B2 (en) | 2010-08-02 | 2017-06-27 | Regeneron Pharmaceuticals, Inc. | Mice that make VL binding proteins |
US9738701B2 (en) | 2003-05-30 | 2017-08-22 | Merus N.V. | Method for selecting a single cell expressing a heterogeneous combination of antibodies |
US9758805B2 (en) | 2012-04-20 | 2017-09-12 | Merus N.V. | Methods and means for the production of Ig-like molecules |
US9765133B2 (en) | 2008-06-27 | 2017-09-19 | Merus N.V. | Antibody producing non-human mammals |
WO2017158421A1 (fr) | 2016-03-14 | 2017-09-21 | University Of Oslo | Immunoglobulines anti-virales synthétiques |
WO2017158436A1 (fr) | 2016-03-17 | 2017-09-21 | Oslo Universitetssykehus Hf | Protéines de fusion ciblant des macrophages associés aux tumeurs pour le traitement du cancer |
WO2017158426A1 (fr) | 2016-03-14 | 2017-09-21 | University Of Oslo | Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée |
WO2017165736A1 (fr) | 2016-03-25 | 2017-09-28 | Visterra, Inc. | Formulations de molécules d'anticorps contre le virus de la dengue |
WO2017165464A1 (fr) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Molécules multispécifiques et multifonctionnelles et leurs utilisations |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
WO2017181098A2 (fr) | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Molécules d'anticorps se liant au virus zika et leurs utilisations |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
EP3248618A1 (fr) | 2009-04-22 | 2017-11-29 | Massachusetts Institute Of Technology | Suppression de l'immunité innée permettant l'administration répétée de longues molécules d'arn |
EP3254687A1 (fr) | 2001-10-04 | 2017-12-13 | Genetics Institute LLC | Procédés et compositions permettant de moduler l'activité du récepteur de l'interleukine 21 |
WO2017221072A2 (fr) | 2016-06-21 | 2017-12-28 | University Of Oslo | Fragments de vaccin de liaison à hla et leurs utilisations |
EP3263581A1 (fr) | 2005-05-17 | 2018-01-03 | University of Connecticut | Compositions et procédés d'immunomodulation dans un organisme |
WO2018013714A1 (fr) | 2016-07-13 | 2018-01-18 | Biogen Ma Inc. | Schémas posologiques d'antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation |
WO2018026748A1 (fr) | 2016-08-01 | 2018-02-08 | Xoma (Us) Llc | Anticorps du récepteur 1 de l'hormone de parathyroïde (pth1r) et leurs utilisations |
WO2018052556A1 (fr) | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Polypeptides synthétiques et leurs utilisations |
US9924705B2 (en) | 2012-03-28 | 2018-03-27 | Kymab Limited | Animal models and therapeutic molecules |
WO2018057955A1 (fr) | 2016-09-23 | 2018-03-29 | Elstar Therapeutics, Inc. | Molécules d'anticorps multispécifiques comprenant des chaînes légères lambda et kappa |
US9932408B2 (en) | 2011-02-25 | 2018-04-03 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US9930871B2 (en) | 2013-02-20 | 2018-04-03 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
US9932398B2 (en) | 2011-10-17 | 2018-04-03 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
WO2018064255A2 (fr) | 2016-09-28 | 2018-04-05 | Xoma (Us) Llc | Anticorps se liant à l'interleukin-2 et leurs utilisations |
US9963716B2 (en) | 2011-09-26 | 2018-05-08 | Kymab Limited | Chimaeric surrogate light chains (SLC) comprising human VpreB |
US9969814B2 (en) | 2010-02-08 | 2018-05-15 | Regeneron Pharmaceuticals, Inc. | Methods for making fully human bispecific antibodies using a common light chain |
WO2018119402A1 (fr) | 2016-12-23 | 2018-06-28 | Visterra, Inc. | Polypeptides de liaison et leurs procédés de production |
WO2018136626A1 (fr) | 2017-01-18 | 2018-07-26 | Visterra, Inc. | Conjugués molécule d'anticorps-médicament et leurs utilisations |
WO2018151820A1 (fr) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles comprenant un ligand trimérique et leurs utilisations |
WO2018158719A1 (fr) | 2017-03-02 | 2018-09-07 | Novartis Ag | Protéines hétérodimères modifiées |
WO2018187227A1 (fr) | 2017-04-03 | 2018-10-11 | Concologie, Inc. | Procédés de traitement du cancer à l'aide d'anticorps ciblant ps avec des agents immuno-oncologiques |
WO2018195283A1 (fr) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Molécules multispécifiques et utilisations correspondantes |
WO2018201047A1 (fr) | 2017-04-28 | 2018-11-01 | Elstar Therapeutics, Inc. | Molécules multispécifiques comprenant un domaine d'hétérodimérisation non immunoglobuline et leurs utilisations |
WO2018201051A1 (fr) | 2017-04-28 | 2018-11-01 | Novartis Ag | Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase |
US10130081B2 (en) | 2011-08-05 | 2018-11-20 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
WO2018222901A1 (fr) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à une protéine de leucémie myéloproliférative (mpl) et leurs utilisations |
US10149462B2 (en) | 2013-10-01 | 2018-12-11 | Kymab Limited | Animal models and therapeutic molecules |
WO2018237173A1 (fr) | 2017-06-22 | 2018-12-27 | Novartis Ag | Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes |
WO2018237157A1 (fr) | 2017-06-22 | 2018-12-27 | Novartis Ag | Molécules d'anticorps se liant à cd73 et leurs utilisations |
WO2019006007A1 (fr) | 2017-06-27 | 2019-01-03 | Novartis Ag | Régimes posologiques pour anticorps anti-tim3 et leurs utilisations |
EP3431496A1 (fr) | 2017-07-19 | 2019-01-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anticorps amyloïdes beta anti-isoasp7 et leurs utilisations |
WO2019018730A1 (fr) | 2017-07-20 | 2019-01-24 | Novartis Ag | Régimes posologiques pour des anticorps anti-lag3 et leurs utilisations |
WO2019035938A1 (fr) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à bcma et leurs utilisations |
US10238093B2 (en) | 2012-06-12 | 2019-03-26 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
EP3461841A1 (fr) | 2017-10-02 | 2019-04-03 | Certest Biotec, S.L. | Anticorps et dispositifs d'essai pour la détection de bactéries du genre campylobacter |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US10253101B2 (en) | 2015-08-06 | 2019-04-09 | Xoma (Us) Llc | Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia |
WO2019070726A1 (fr) | 2017-10-02 | 2019-04-11 | Visterra, Inc. | Molécules d'anticorps se liant à cd73 et leurs utilisations |
WO2019077132A1 (fr) | 2017-10-19 | 2019-04-25 | Debiopharm International S.A. | Produit de combinaison pour le traitement du cancer |
WO2019099838A1 (fr) | 2017-11-16 | 2019-05-23 | Novartis Ag | Polythérapies |
WO2019113464A1 (fr) | 2017-12-08 | 2019-06-13 | Elstar Therapeutics, Inc. | Molécules multispécifiques et utilisations correspondantes |
WO2019129137A1 (fr) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anticorps anti-lag-3 et utilisations associées |
WO2019129136A1 (fr) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anticorps anti-pd-l1 et ses applications |
EP3514179A1 (fr) | 2014-01-24 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | Molécules d'anticorps anti-pd-1 et leurs utilisations |
WO2019178362A1 (fr) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles se liant à calréticuline et utilisations associees |
WO2019178364A2 (fr) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles et utilisations associées |
US10435467B2 (en) | 2015-01-08 | 2019-10-08 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
WO2019200229A1 (fr) | 2018-04-13 | 2019-10-17 | Novartis Ag | Régimes posologiques pour anticorps anti-pd-l1 et utilisations associées |
WO2019232244A2 (fr) | 2018-05-31 | 2019-12-05 | Novartis Ag | Molécules d'anticorps anti-cd73 et leurs utilisations |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
WO2019246293A2 (fr) | 2018-06-19 | 2019-12-26 | Atarga, Llc | Molécules d'anticorps se liant au composant du complément 5 et leurs utilisations |
WO2020010250A2 (fr) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Molécules d'anticorps anti-tcr et leurs utilisations |
WO2020021465A1 (fr) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Procédé de traitement de tumeurs neuroendocrines |
WO2020069372A1 (fr) | 2018-09-27 | 2020-04-02 | Elstar Therapeutics, Inc. | Molécules multispécifiques csf1r/ccr2 |
US10667501B2 (en) | 2012-05-17 | 2020-06-02 | Kymab Limited | Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins |
WO2020128898A1 (fr) | 2018-12-20 | 2020-06-25 | Novartis Ag | Combinaisons pharmaceutiques |
WO2020165868A1 (fr) | 2019-02-15 | 2020-08-20 | Perkinelmer Cellular Technologies Germany Gmbh | Pré-balayage d'objectif de microscope à faible puissance et balayage d'objectif de microscope à haute puissance dans une direction x, y et z pour imager des objets tels que des cellules à l'aide d'un microscope |
WO2020172601A1 (fr) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles se liant à la calréticuline et utilisations associées |
WO2020172571A1 (fr) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles se liant à des cellules cancéreuses associées à des lymphocytes t et leurs utilisations |
WO2020172598A1 (fr) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles se liant à des lymphocytes t et leurs utilisations pour traiter des troubles auto-immuns |
WO2020172605A1 (fr) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Molécules d'anticorps se liant à nkp30 et utilisations associees |
WO2020172596A1 (fr) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Molécules d'anticorps anti-tcr et leurs utilisations |
US10787522B2 (en) | 2014-03-21 | 2020-09-29 | Regeneron Pharmaceuticals, Inc. | VL antigen binding proteins exhibiting distinct binding characteristics |
EP3714906A1 (fr) | 2007-10-03 | 2020-09-30 | Cornell University | Traitement de troubles prolifératifs utilisant des anticorps psma radiomarqués |
WO2020205523A1 (fr) | 2019-03-29 | 2020-10-08 | Atarga, Llc | Anticorps anti-fgf23 |
WO2020257289A2 (fr) | 2019-06-17 | 2020-12-24 | Visterra, Inc. | Molécules d'anticorps humanisés se liant à cd138 et leurs utilisations |
US10881085B2 (en) | 2014-03-21 | 2021-01-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
WO2021021606A1 (fr) | 2019-07-26 | 2021-02-04 | Visterra, Inc. | Agents d'interleukine 2 et utilisations de ceux-ci |
US10934571B2 (en) | 2002-07-18 | 2021-03-02 | Merus N.V. | Recombinant production of mixtures of antibodies |
WO2021079188A1 (fr) | 2019-10-21 | 2021-04-29 | Novartis Ag | Polythérapies comprenant du vénétoclax et des inhibiteurs de tim-3 |
WO2021079195A1 (fr) | 2019-10-21 | 2021-04-29 | Novartis Ag | Inhibiteurs de tim-3 et leurs utilisations |
WO2021123902A1 (fr) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combinaison d'anticorps anti-tim-3 mbg453 et d'anticorps anti-tgf-bêta nis793, avec ou sans décitabine ou l'anticorps anti pd-1 spartalizumab, pour le traitement de la myélofibrose et du syndrome myélodysplasique |
US11051497B2 (en) | 2011-09-19 | 2021-07-06 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
WO2021138407A2 (fr) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Molécules multifonctionnelles se liant à cd33 et utilisations associées |
WO2021146320A1 (fr) | 2020-01-13 | 2021-07-22 | Visterra, Inc. | Molécules d'anticorps anti-c5ar1 et leurs utilisations |
WO2021144657A1 (fr) | 2020-01-17 | 2021-07-22 | Novartis Ag | Polythérapies comprenant un inhibiteur tim-3 et un agent d'hypométhylation à utiliser dans le traitement du syndrome myélodysplasique ou de la leucémie myélomonocytaire chronique |
US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
WO2021203024A1 (fr) | 2020-04-03 | 2021-10-07 | Visterra, Inc. | Conjugués molécule d'anticorps-médicament et leurs utilisations |
WO2021217085A1 (fr) | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Molécules multifonctionnelles se liant à des cellules cancéreuses associées à des lymphocytes t et leurs utilisations |
WO2021220218A1 (fr) | 2020-05-01 | 2021-11-04 | Novartis Ag | Variants d'immunoglobuline |
WO2021220215A1 (fr) | 2020-05-01 | 2021-11-04 | Novartis Ag | Immunoglobulines modifiées |
US11179377B2 (en) | 2017-03-10 | 2021-11-23 | Embera Neurotherapeutics, Inc. | Pharmaceutical compositions and uses thereof |
WO2021262999A1 (fr) | 2020-06-24 | 2021-12-30 | Visterra, Inc. | Molécules d'anticorps contre april et leurs utilisations |
WO2022026592A2 (fr) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Molécules d'anticorps contre le coronavirus et leurs utilisations |
WO2022043558A1 (fr) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Méthode de traitement de cancers exprimant le psma |
WO2022046920A2 (fr) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Molécules multifonctionnelles se liant à la calréticuline et utilisations associées |
WO2022046922A2 (fr) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Molécules d'anticorps se liant à nkp30 et utilisations associees |
WO2022043557A1 (fr) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Méthode de traitement de cancers exprimant le psma |
WO2022047046A1 (fr) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Procédés de détection de trbc1 ou de trbc2 |
WO2022120224A1 (fr) | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Procédés d'utilisation d'agents d'interleukine-2 |
WO2022159590A1 (fr) | 2021-01-20 | 2022-07-28 | Visterra, Inc. | Mutants d'interleukine-2 et leurs utilisations |
WO2022162569A1 (fr) | 2021-01-29 | 2022-08-04 | Novartis Ag | Régimes posologiques d'anticorps anti-cd73 et anti-entpd2 et leurs utilisations |
WO2022182872A2 (fr) | 2021-02-24 | 2022-09-01 | Alladapt Immunotherapeutics, Inc. | Compositions et méthodes pour l'identification de protéines allergènes à réactivité croisée et traitement d'allergies |
WO2022195551A1 (fr) | 2021-03-18 | 2022-09-22 | Novartis Ag | Biomarqueurs pour le cancer et leurs méthodes d'utilisation |
WO2022216993A2 (fr) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Molécules multifonctionnelles se liant au tcr et leurs utilisations |
WO2022215011A1 (fr) | 2021-04-07 | 2022-10-13 | Novartis Ag | UTILISATIONS D'ANTICORPS ANTI-TGFβ ET D'AUTRES AGENTS THÉRAPEUTIQUES POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES |
US11512131B2 (en) | 2017-12-27 | 2022-11-29 | Innovent Biologies (Suzhou) Co., Ltd. | Anti-PD-L1 antibody and uses thereof |
US11564380B2 (en) | 2009-07-08 | 2023-01-31 | Kymab Limited | Animal models and therapeutic molecules |
US11572405B2 (en) | 2018-01-12 | 2023-02-07 | Bristol-Myers Squibb Company | Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer |
WO2023044483A2 (fr) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions et procédés pour le traitement du cancer positif her2 |
WO2023092004A1 (fr) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions et méthodes pour le traitement de troubles liés à tau |
WO2023097254A1 (fr) | 2021-11-24 | 2023-06-01 | Visterra, Inc. | Molécules modifiées d'anticorps anti-cd138 et leurs utilisations |
WO2023102463A1 (fr) | 2021-12-01 | 2023-06-08 | Visterra, Inc. | Procédés d'utilisation d'agents d'interleukine-2 |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
WO2023139292A1 (fr) | 2022-01-24 | 2023-07-27 | Cambridge Enterprise Limited | Thérapie anti-tau |
WO2023150778A1 (fr) | 2022-02-07 | 2023-08-10 | Visterra, Inc. | Molécules d'anticorps anti-idiotype et leurs utilisations |
US11725247B2 (en) | 2016-02-29 | 2023-08-15 | Foundation Medicine, Inc. | Methods of treating cancer |
WO2023212518A1 (fr) | 2022-04-25 | 2023-11-02 | Visterra, Inc. | Molécules d'anticorps contre april et leurs utilisations |
WO2023220695A2 (fr) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions et procédés pour le traitement du cancer her2 positif |
EP4296279A1 (fr) | 2022-06-23 | 2023-12-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Protéines de liaison anti-transthyrétine (ttr) et leurs utilisations |
WO2024030976A2 (fr) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions et procédés permettant le franchissement de la barrière hémato-encéphalique |
EP4324518A2 (fr) | 2014-01-31 | 2024-02-21 | Novartis AG | Molécules d'anticorps anti-tim-3 et leurs utilisations |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990004036A1 (fr) * | 1988-10-12 | 1990-04-19 | Medical Research Council | Production d'anticorps a partir d'animaux transgeniques |
-
1990
- 1990-07-11 WO PCT/US1990/003894 patent/WO1991000906A1/fr unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990004036A1 (fr) * | 1988-10-12 | 1990-04-19 | Medical Research Council | Production d'anticorps a partir d'animaux transgeniques |
Non-Patent Citations (1)
Title |
---|
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 86, no. 7, September 1989, WASHINGTON US pages 6709 - 6713; BRUGGEMANN, M. et al.: "A repertoire of monoclonal antibodies with human heavy chains from transgenic mice" see the whole document * |
Cited By (404)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0546073A1 (fr) * | 1990-08-29 | 1993-06-16 | Genpharm Int | Animaux non humains transgeniques capables de produire des anticorps heterologues. |
EP0546073A4 (fr) * | 1990-08-29 | 1994-04-27 | Genpharm International, Inc. | |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0814159A2 (fr) * | 1990-08-29 | 1997-12-29 | GenPharm International, Inc. | Animaux transgéniques non humains capables de produire des anticorps hétérologues |
US5569825A (en) * | 1990-08-29 | 1996-10-29 | Genpharm International | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0814159A3 (fr) * | 1990-08-29 | 1999-07-14 | GenPharm International, Inc. | Animaux transgéniques non humains capables de produire des anticorps hétérologues |
US5877397A (en) * | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) * | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) * | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7501552B2 (en) | 1991-08-28 | 2009-03-10 | Medarex, Inc. | Transgenic non-human animals for producing chimeric antibodies |
EP0746609A4 (fr) * | 1991-12-17 | 1997-12-17 | Genpharm Int | Animaux transgeniques non humains capables de produire des anticorps heterologues |
AU781922B2 (en) * | 1991-12-17 | 2005-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
AU743883B2 (en) * | 1991-12-17 | 2002-02-07 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0746609A1 (fr) * | 1991-12-17 | 1996-12-11 | Genpharm International | Animaux transgeniques non humains capables de produire des anticorps heterologues |
WO1994025585A1 (fr) * | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Animaux transgeniques capables de produire des anticorps heterologues |
US8158419B2 (en) | 1994-03-09 | 2012-04-17 | Medarex, Inc. | Transgenic non-human animals for producing chimeric antibodies |
US8293480B2 (en) | 1994-03-09 | 2012-10-23 | Genpharm International | Transgenic non-human animals for producing chimeric antibodies |
EP1958966A2 (fr) | 1994-07-01 | 2008-08-20 | Dana-Farber Cancer Institute | Procédé pour moduler des réponses de lymphocytes T en manipulant une chaîne gamma de récepteur de cytokine courante |
WO1996034096A1 (fr) * | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Anticorps humains derives de xeno-souris immunisees |
WO1997013852A1 (fr) * | 1995-10-10 | 1997-04-17 | Genpharm International, Inc. | Animaux non humains transgeniques pouvant produire des anticorps heterologues |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0939763A1 (fr) * | 1996-03-20 | 1999-09-08 | Abgenix, Inc. | Recombinaison dirigee de l'adn a mediation par transition |
EP1714971A2 (fr) * | 1996-03-20 | 2006-10-25 | Amgen Fremont Inc. | Recombinaison dirigée de l'ADN à médiation par transition |
EP1714971A3 (fr) * | 1996-03-20 | 2007-05-09 | Amgen Fremont Inc. | Recombinaison dirigée de l'ADN à médiation par transition |
EP0939763A4 (fr) * | 1996-03-20 | 2002-05-08 | Abgenix Inc | Recombinaison dirigee de l'adn a mediation par transition |
US7722873B2 (en) | 1996-10-10 | 2010-05-25 | Genpharm International, Inc. | Heterologous antibodies which bind human CD4 |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
US8231877B2 (en) | 1996-10-10 | 2012-07-31 | Genpharm International, Inc. | Heterologous antibodies which bind human CD4 |
US7820877B2 (en) | 1996-12-03 | 2010-10-26 | Amgen Fremont Inc. | Transgenic mammals having human IG loci including plural Vh and Vk regions and antibodies produced therefrom |
WO1998024893A2 (fr) * | 1996-12-03 | 1998-06-11 | Abgenix, Inc. | MAMMIFERES TRANSGENIQUES POSSEDANT DES LOCI DE GENES D'IMMUNOGLOBULINE D'ORIGINE HUMAINE, DOTES DE REGIONS VH ET Vλ, ET ANTICORPS PRODUITS A PARTIR DE TELS MAMMIFERES |
EP1972194A1 (fr) * | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Mammifères transgéniques disposant d'un loci ig comprenant plusieurs régions vh et vk et anticorps produits à partir de ceux-ci |
WO1998024893A3 (fr) * | 1996-12-03 | 1998-08-20 | Abgenix Inc | MAMMIFERES TRANSGENIQUES POSSEDANT DES LOCI DE GENES D'IMMUNOGLOBULINE D'ORIGINE HUMAINE, DOTES DE REGIONS VH ET Vλ, ET ANTICORPS PRODUITS A PARTIR DE TELS MAMMIFERES |
AU2008200005B2 (en) * | 1996-12-03 | 2012-05-17 | Amgen Fremont Inc. | Transgenic Mammals Having Human Ig Loci Including Plural Vh and Vk Regions and Antibodies Produced Therefrom |
US8809051B2 (en) | 1996-12-03 | 2014-08-19 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vκ regions and antibodies produced therefrom |
US7064244B2 (en) | 1996-12-03 | 2006-06-20 | Abgenix, Inc. | Transgenic mammals having human Ig loci including plural VH and VK regions and antibodies produced therefrom |
US8227580B2 (en) | 1997-05-05 | 2012-07-24 | Amgen Inc | Human monoclonal antibodies to epidermal growth factor receptor |
US7807798B2 (en) | 1997-05-05 | 2010-10-05 | Amgen Fremont Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
EP2251026A1 (fr) | 2000-06-08 | 2010-11-17 | Immune Disease Institute, Inc. | Procédés et compositions pour l'inhibition de lésions de reperfusion à médiation par immunoglobulines |
US9677129B2 (en) | 2000-10-31 | 2017-06-13 | Regeneron Pharmaceuticals, Inc. | Method for detecting the replacement of an endogenous allele with a modified allele by homologous recombination in a mouse ES cell |
US8759105B2 (en) | 2000-10-31 | 2014-06-24 | Regeneron Pharmaceuticals, Inc. | Method for genetically modifying mouse embryonic stem cell by homologous recombination |
US8791323B2 (en) | 2000-10-31 | 2014-07-29 | Regeneron Pharmaceuticals, Inc. | Hybrid antibodies comprising human variable regions and mouse constant regions produced in a genetically modified mouse |
US8846402B2 (en) | 2000-10-31 | 2014-09-30 | Regeneron Pharmaceuticals, Inc. | Method for genetically modifying isolated non-human mammalian cell by homologous recombination |
US9708635B2 (en) | 2000-10-31 | 2017-07-18 | Regeneron Pharmaceuticals, Inc. | Methods of making a nucleic acid encoding a human variable region |
US10227625B2 (en) | 2000-10-31 | 2019-03-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US10344299B2 (en) | 2000-10-31 | 2019-07-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for modifying cells |
US9376699B2 (en) | 2000-10-31 | 2016-06-28 | Regeneron Pharmaceuticals, Inc. | Methods of producing hybrid antibodies |
US8835712B2 (en) | 2000-11-30 | 2014-09-16 | Medarex, L.L.C. | Transgenic trasnchromosomal rodents for making human antibodies |
US9426970B2 (en) | 2000-11-30 | 2016-08-30 | E. R. Squibb & Sons, L.L.C. | Transgenic transchromosomal rodents for making human antibodies |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US7816578B2 (en) | 2000-11-30 | 2010-10-19 | Kyowa Hakko Kirin Co., Ltd. | Transgenic transchromosomal rodents for making human antibodies |
US7576258B2 (en) | 2000-11-30 | 2009-08-18 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US10076103B2 (en) | 2000-11-30 | 2018-09-18 | Kyowa Hakko Kirin Co., Ltd. | Transgenic transchromosomal rodents for making human antibodies |
US10584364B2 (en) * | 2000-12-07 | 2020-03-10 | Rgeneron Pharmaceuticals, Inc. | Mice that produce hybrid antibodies |
US10378039B2 (en) | 2001-02-16 | 2019-08-13 | Regeneron Pharmaceuticals, Inc. | Mouse embryonic stem cells comprising a hybrid heavy chain immunoglobulin locus |
US10526630B2 (en) | 2001-02-16 | 2020-01-07 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice that produce hybrid antibodies |
US20140017238A1 (en) | 2001-02-16 | 2014-01-16 | Regeneron Pharmaceuticals, Inc. | Methods of Modifying Eukaryotic Cells |
EP2787075A1 (fr) * | 2001-02-16 | 2014-10-08 | Regeneron Pharmaceuticals, Inc. | Rongeur capapble de produire des anticorps hybrides contenant des régions variables humaines et des régions constantes de rongeurs |
US10378040B2 (en) | 2001-02-16 | 2019-08-13 | Regeneron Pharmaceuticals, Inc. | Mice that produce hybrid antibodies |
US20140013457A1 (en) * | 2001-02-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Methods of Modifying Eukaryotic Cells |
EP3626819A1 (fr) * | 2001-02-16 | 2020-03-25 | Regeneron Pharmaceuticals, Inc. | Souris transgénique produisant des anticorps hybrides contenant des régions variables humaines et des régions constantes de souris |
US10378038B2 (en) | 2001-02-16 | 2019-08-13 | Regeneron Pharmaceuticals, Inc. | Mice that produce hybrid antibodies |
EP3085779B1 (fr) | 2001-02-16 | 2019-04-03 | Regeneron Pharmaceuticals, Inc. | Procédés de modification des cellules eucaryotes |
EP2264163A2 (fr) | 2001-02-16 | 2010-12-22 | Regeneron Pharmaceuticals, Inc. | Procédés de modification de cellules eucaryotes |
US10378037B2 (en) | 2001-02-16 | 2019-08-13 | Regeneron Pharmaceuticals, Inc. | Methods of making a nucleic acid encoding a human variable region |
US9528136B2 (en) | 2001-02-16 | 2016-12-27 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
EP2264163B1 (fr) * | 2001-02-16 | 2015-10-14 | Regeneron Pharmaceuticals, Inc. | Procédés de modification de cellules eucaryotes |
US9388446B2 (en) | 2001-02-16 | 2016-07-12 | Regeneron Pharmaceuticals, Inc. | Methods of producing hybrid antibodies |
EP2787075B1 (fr) | 2001-02-16 | 2016-11-30 | Regeneron Pharmaceuticals, Inc. | Rongeur capable de produire des anticorps hybrides contenant des régions variables humaines et des régions constantes de rongeurs |
US9353394B2 (en) | 2001-02-16 | 2016-05-31 | Regeneron Pharmaceuticals, Inc. | Methods of producing hybrid antibodies |
EP2786657B1 (fr) | 2001-02-16 | 2018-02-07 | Regeneron Pharmaceuticals, Inc. | Procédé de production d'un anticorps comprenant une région variable humaine et une région constante de rongeur. |
US9382567B2 (en) | 2001-02-16 | 2016-07-05 | Regeneron Pharmaceuticals, Inc. | Methods of producing hybrid antibodies |
EP2767588A1 (fr) * | 2001-02-16 | 2014-08-20 | Regeneron Pharmaceuticals, Inc. | Procédés de modification des cellules eucaryotes |
US9371553B2 (en) | 2001-02-16 | 2016-06-21 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice that produce hybrid antibodies |
US20140073010A1 (en) * | 2001-02-16 | 2014-03-13 | Regeneron Pharmaceuticals, Inc. | Methods of Modifying Eukaryotic Cells |
US10640800B2 (en) | 2001-02-16 | 2020-05-05 | Regeneron Pharmaceuticals, Inc. | Mice that produce hybrid antibodies |
US10448622B2 (en) | 2001-05-11 | 2019-10-22 | E. R. Squibb & Sons, L.L.C. | Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission |
US9499838B2 (en) | 2001-05-11 | 2016-11-22 | Kyowa Hakko Kirin Co., Ltd. | Human artificial chromosome containing human antibody λ light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission |
EP2277542A1 (fr) | 2001-06-01 | 2011-01-26 | Cornell Research Foundation Inc. | Anticorps modifiés dirigés contre l'antigène prostatique spécifique membranaire et utilisations associées |
US7745391B2 (en) | 2001-09-14 | 2010-06-29 | Compugen Ltd. | Human thrombospondin polypeptide |
EP3254687A1 (fr) | 2001-10-04 | 2017-12-13 | Genetics Institute LLC | Procédés et compositions permettant de moduler l'activité du récepteur de l'interleukine 21 |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
US10934571B2 (en) | 2002-07-18 | 2021-03-02 | Merus N.V. | Recombinant production of mixtures of antibodies |
US8105588B2 (en) | 2002-12-16 | 2012-01-31 | Genmab A/S | Human monoclonal antibodies against interleukin 8 (IL-8) |
US10066012B2 (en) | 2002-12-16 | 2018-09-04 | Cormorant Pharmaceuticals Ab | Human monoclonal antibodies against interleukin 8 (IL-8) |
US10253093B2 (en) | 2002-12-16 | 2019-04-09 | Cormorant Pharmaceuticals Ab | Human monoclonal antibodies against interleukin 8 (IL-8) |
US8603469B2 (en) | 2002-12-16 | 2013-12-10 | Genmab A/S | Methods of treating cancer with human monoclonal antibodies against interleukin 8 |
US11339215B2 (en) | 2002-12-16 | 2022-05-24 | Cormorant Pharmaceuticals Ab | Methods of treating cancer with human monoclonal antibodies against interleukin 8 (IL-8) |
US7282568B2 (en) | 2002-12-16 | 2007-10-16 | Medarex, Inc. | Human monoclonal antibodies against interleukin 8 (IL-8) |
US7622559B2 (en) | 2002-12-16 | 2009-11-24 | Genmab A/S | Human monoclonal antibodies against interleukin 8 (IL-8) |
EP2386318A1 (fr) | 2003-05-15 | 2011-11-16 | Iogenetics, Inc. | Biocides ciblés |
US9738701B2 (en) | 2003-05-30 | 2017-08-22 | Merus N.V. | Method for selecting a single cell expressing a heterogeneous combination of antibodies |
US10605808B2 (en) | 2003-05-30 | 2020-03-31 | Merus N.V. | Antibody producing non-human animals |
US10670599B2 (en) | 2003-05-30 | 2020-06-02 | Merus N.V. | Method for selecting a single cell expressing a heterogeneous combination of antibodies |
EP2508608A1 (fr) | 2003-06-09 | 2012-10-10 | Alnylam Pharmaceuticals Inc. | Procédé de traitement d'une maladie neurodégénérative |
EP2290077A2 (fr) | 2004-03-01 | 2011-03-02 | Immune Disease Institute, Inc. | Anticorps naturels IgM et leur inhibiteurs |
US7704503B2 (en) | 2005-02-14 | 2010-04-27 | Wyeth Llc | Use of IL-17F in diagnosis and therapy of airway inflammation |
EP2436695A1 (fr) | 2005-04-14 | 2012-04-04 | Wyeth LLC | Méthodes de traitement et de prévention de la fibrose par des antagonistes de l'IL-21/IL-21R |
EP3263581A1 (fr) | 2005-05-17 | 2018-01-03 | University of Connecticut | Compositions et procédés d'immunomodulation dans un organisme |
EP3805245A1 (fr) | 2005-05-17 | 2021-04-14 | University of Connecticut | Compositions et methodes d'immunomodulation d'un organisme |
US9309315B2 (en) | 2005-08-18 | 2016-04-12 | Genmab A/S | Therapy with CD4 binding peptides and radiation |
EP2478918A2 (fr) | 2005-11-10 | 2012-07-25 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions et procédés pour le traitement de l'addiction et autres troubles neuropsychiatriques |
US9415107B2 (en) | 2005-11-10 | 2016-08-16 | Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College | Compositions and methods for the treatment of addiction and other neuropsychiatric disorders |
EP1798240A1 (fr) | 2005-12-15 | 2007-06-20 | Industrial Technology Research Institute | Polypeptides recombinants à structure en triple helice |
EP2336170A2 (fr) | 2005-12-15 | 2011-06-22 | Industrial Technology Research Institute | Polypeptides recombinants à structure en triple hélice |
US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
EP2338912A2 (fr) | 2005-12-15 | 2011-06-29 | Industrial Technology Research Institute | Polypeptides recombinants à structure en triple hélice |
US8278421B2 (en) | 2006-03-20 | 2012-10-02 | Xoma Techolology Ltd. | Human antibodies specific for gastrin materials and methods |
US9220244B2 (en) | 2006-03-31 | 2015-12-29 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
EP2003960B1 (fr) | 2006-03-31 | 2015-06-10 | E. R. Squibb & Sons, L.L.C. | Animaux transgéniques exprimant des anticorps chimériques destinés à être utilisés pour la préparation d'anticorps humains |
US7910798B2 (en) | 2006-03-31 | 2011-03-22 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
US8232449B2 (en) | 2006-03-31 | 2012-07-31 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
EP2471815A1 (fr) | 2006-07-11 | 2012-07-04 | University Of Medicine And Dentistry Of New Jersey | Protéines, acides nucléiques codant pour celles-ci et procédés d'utilisation correspondants |
EP2471809A1 (fr) | 2006-07-11 | 2012-07-04 | University Of Medicine And Dentistry Of New Jersey | Protéines, acides nucléiques codant pour celles-ci et procédés d'utilisation correspondants |
WO2008060776A2 (fr) | 2006-10-03 | 2008-05-22 | University Of Medicine And Dentistry Of New Jersey | Peptides atap, acides nucléiques le codant et procédés d'utilisation correspondants |
EP3124045A2 (fr) | 2006-12-20 | 2017-02-01 | Xoma (Us) Llc | Traitement de maladies apparentées il-1 beta |
EP3714906A1 (fr) | 2007-10-03 | 2020-09-30 | Cornell University | Traitement de troubles prolifératifs utilisant des anticorps psma radiomarqués |
EP2065402A1 (fr) | 2007-11-30 | 2009-06-03 | Industrial Technology Research Institut | Anticorps de base de collagène trimérique |
EP2851373A1 (fr) | 2007-12-20 | 2015-03-25 | Xoma (Us) Llc | Procédés pour le traitement de la goutte |
WO2009086003A1 (fr) | 2007-12-20 | 2009-07-09 | Xoma Technology Ltd. | Procédés pour le traitement de la goutte |
US8653020B2 (en) | 2008-01-25 | 2014-02-18 | Aarhus Universitet | Selective exosite inhibition of PAPP-A activity against IGFBP-4 |
EP2732823A1 (fr) | 2008-06-25 | 2014-05-21 | H. Lundbeck A/S | Modulation de la trpV : Système de récepteur du domaine vps10p pour le traitement de la douleur |
US9951124B2 (en) | 2008-06-27 | 2018-04-24 | Merus N.V. | Antibody producing non-human mammals |
US11559049B2 (en) | 2008-06-27 | 2023-01-24 | Merus N.V. | Antibody producing non-human animals |
US9944695B2 (en) | 2008-06-27 | 2018-04-17 | Merus N.V. | Antibody producing non-human mammals |
US9765133B2 (en) | 2008-06-27 | 2017-09-19 | Merus N.V. | Antibody producing non-human mammals |
US11785924B2 (en) | 2008-06-27 | 2023-10-17 | Merus N.V. | Antibody producing non-human animals |
US10966411B2 (en) | 2008-06-27 | 2021-04-06 | Merus N.V. | Antibody producing non-human mammals |
US11237165B2 (en) | 2008-06-27 | 2022-02-01 | Merus N.V. | Antibody producing non-human animals |
US11925174B2 (en) | 2008-06-27 | 2024-03-12 | Merus N.V. | Antibody producing non-human animals |
US10638736B2 (en) | 2008-09-30 | 2020-05-05 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US10575504B2 (en) | 2008-09-30 | 2020-03-03 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US9346873B2 (en) | 2008-09-30 | 2016-05-24 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US10561123B2 (en) | 2008-09-30 | 2020-02-18 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US10555506B2 (en) | 2008-09-30 | 2020-02-11 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US10492476B2 (en) | 2008-09-30 | 2019-12-03 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
WO2010069331A2 (fr) | 2008-12-19 | 2010-06-24 | H. Lundbeck A/S | Modulation de la famille de récepteurs à domaine vps10p pour le traitement de troubles mentaux et comportementaux |
EP3165537A1 (fr) | 2008-12-19 | 2017-05-10 | H. Lundbeck A/S | Modulation de la famille de récepteurs à domaine vps10 pour le traitement de troubles mentaux et du comportement |
WO2010075475A1 (fr) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anticorps tyrosine kinase du type fms soluble (sflt-1) et composition associée, trousse, procédés d'utilisation, matériaux et procédé de fabrication |
WO2010112034A2 (fr) | 2009-04-02 | 2010-10-07 | Aarhus Universitet | Compositions et méthodes pour le traitement et le diagnostic de synucléinopathies |
EP3524275A1 (fr) | 2009-04-22 | 2019-08-14 | Massachusetts Institute Of Technology | Suppression immunitaire innée permettant la distribution répétée de longues molécules d'arn |
EP3248618A1 (fr) | 2009-04-22 | 2017-11-29 | Massachusetts Institute Of Technology | Suppression de l'immunité innée permettant l'administration répétée de longues molécules d'arn |
US10064398B2 (en) | 2009-07-08 | 2018-09-04 | Kymab Limited | Animal models and therapeutic molecules |
US9505827B2 (en) | 2009-07-08 | 2016-11-29 | Kymab Limited | Animal models and therapeutic molecules |
US9504236B2 (en) | 2009-07-08 | 2016-11-29 | Kymab Limited | Animal models and therapeutic molecules |
US11606941B2 (en) | 2009-07-08 | 2023-03-21 | Kymab Limited | Animal models and therapeutic molecules |
US9447177B2 (en) | 2009-07-08 | 2016-09-20 | Kymab Limited | Transgenic mouse homozygous for chimeric IgH locus |
US11812731B2 (en) | 2009-07-08 | 2023-11-14 | Kymab Ltd. | Animal models and therapeutic molecules |
US11564380B2 (en) | 2009-07-08 | 2023-01-31 | Kymab Limited | Animal models and therapeutic molecules |
US10165763B2 (en) | 2009-07-08 | 2019-01-01 | Kymab Limited | Animal models and therapeutic molecules |
US9434782B2 (en) | 2009-07-08 | 2016-09-06 | Kymab Limited | Animal models and therapeutic molecules |
EP3187877A1 (fr) | 2009-09-25 | 2017-07-05 | XOMA Technology Ltd. | Procédés de criblage |
EP2957296A1 (fr) | 2009-09-25 | 2015-12-23 | Xoma (Us) Llc | Anticorps se liant au récepteur de l'insuline |
WO2011038301A2 (fr) | 2009-09-25 | 2011-03-31 | Xoma Technology Ltd. | Procédés de criblage |
WO2011038302A2 (fr) | 2009-09-25 | 2011-03-31 | Xoma Technology Ltd. | Nouveaux modulateurs |
EP2501817B2 (fr) † | 2010-02-08 | 2021-04-21 | Regeneron Pharmaceuticals, Inc. | Souris à chaîne légère commune |
US10412940B2 (en) | 2010-02-08 | 2019-09-17 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
EP2505654B1 (fr) | 2010-02-08 | 2016-08-24 | Regeneron Pharmaceuticals, Inc. | Souris à chaîne légère commune |
EP2501817B1 (fr) | 2010-02-08 | 2015-08-26 | Regeneron Pharmaceuticals, Inc. | Souris à chaîne légère commune |
US9969814B2 (en) | 2010-02-08 | 2018-05-15 | Regeneron Pharmaceuticals, Inc. | Methods for making fully human bispecific antibodies using a common light chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US11026407B2 (en) | 2010-02-08 | 2021-06-08 | Regeneran Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US10167344B2 (en) | 2010-02-08 | 2019-01-01 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US10986820B2 (en) | 2010-02-08 | 2021-04-27 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
EP2505654B2 (fr) † | 2010-02-08 | 2020-05-13 | Regeneron Pharmaceuticals, Inc. | Souris à chaîne légère commune |
WO2011116023A1 (fr) | 2010-03-18 | 2011-09-22 | Abbott Laboratories | Procédé permettant d'analyser la lipocaline urinaire associée à la gélatinase des polynucléaires neutrophiles (ungal) dans le pronostic de la fonction de transplantation rénale cadavérique chez un patient, y compris un patient chez lequel a été diagnostiquée une reprise retardée de la fonction du greffon (dgf), procédé permettant d'analyser la ungal dans l'évaluation du risque de dgf chez un patient chez lequel a été diagnostiquée une reprise avancée de la fonction du greffon (egf), et kits afférents |
WO2011119484A1 (fr) | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Procédés bioinformatiques pour déterminer la liaison de peptides |
EP4012714A1 (fr) | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Procédés bioinformatiques pour déterminer la liaison de peptides |
US11104743B2 (en) | 2010-03-31 | 2021-08-31 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10618977B2 (en) | 2010-03-31 | 2020-04-14 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10662255B2 (en) | 2010-03-31 | 2020-05-26 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10494445B2 (en) | 2010-03-31 | 2019-12-03 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10604587B2 (en) | 2010-03-31 | 2020-03-31 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10829564B2 (en) | 2010-03-31 | 2020-11-10 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10836832B2 (en) | 2010-03-31 | 2020-11-17 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US11220555B2 (en) | 2010-03-31 | 2022-01-11 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10626188B2 (en) | 2010-03-31 | 2020-04-21 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US11104744B2 (en) | 2010-03-31 | 2021-08-31 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US10526420B2 (en) | 2010-03-31 | 2020-01-07 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US9580491B2 (en) | 2010-03-31 | 2017-02-28 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US11352444B2 (en) | 2010-03-31 | 2022-06-07 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US11242409B2 (en) | 2010-03-31 | 2022-02-08 | Ablexis, Llc | Genetic engineering of non-human animals for the production of chimeric antibodies |
US9987286B2 (en) | 2010-06-16 | 2018-06-05 | Embera Neurotherapeutics, Inc. | Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease |
US9078886B2 (en) | 2010-06-16 | 2015-07-14 | Embera Neurotherapeutics, Inc. | Compositions for the treatment of addiction, psychiatric disorders, and neurodegenerative disease |
US9551714B2 (en) | 2010-06-25 | 2017-01-24 | Abbott Laboratories | Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies |
WO2011163558A1 (fr) | 2010-06-25 | 2011-12-29 | Abbott Laboratories | Matériaux et procédés pour le dosage d'anticorps anti-virus de l'hépatite c (hvc) |
WO2012010321A1 (fr) | 2010-07-23 | 2012-01-26 | Erasmus University Medical Center Rotterdam | Inhibiteur de l'hémoglobine fœtale |
WO2012010855A1 (fr) | 2010-07-23 | 2012-01-26 | Medical Research Council | Immunité intracellulaire |
US10954310B2 (en) | 2010-08-02 | 2021-03-23 | Regeneran Pharmaceuticals, Inc. | Mice that make VL binding proteins |
US9686970B2 (en) | 2010-08-02 | 2017-06-27 | Regeneron Pharmaceuticals, Inc. | Mice that make VL binding proteins |
WO2012064674A1 (fr) | 2010-11-09 | 2012-05-18 | Abbott Laboratories | Matériels et méthodes pour un immunoessai permettant d'analyser les ptérines |
US9932408B2 (en) | 2011-02-25 | 2018-04-03 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US10905109B2 (en) | 2011-02-25 | 2021-02-02 | Regeneren Pharmaceuticals, Inc. | ADAM6 mice |
US10577430B2 (en) | 2011-02-25 | 2020-03-03 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US11950578B2 (en) | 2011-02-25 | 2024-04-09 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US10694725B2 (en) | 2011-02-25 | 2020-06-30 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US10072095B2 (en) | 2011-02-25 | 2018-09-11 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US10905108B2 (en) | 2011-02-25 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
US9944716B2 (en) | 2011-02-25 | 2018-04-17 | Regeneron Pharmaceuticals, Inc. | ADAM6 mice |
EP2701499B1 (fr) | 2011-04-25 | 2016-02-10 | Regeneron Pharmaceuticals, Inc. | Animaux non humains exprimant des anticorps possédant une chaîne légère commune |
WO2012167143A1 (fr) | 2011-06-03 | 2012-12-06 | Xoma Technology Ltd. | Anticorps spécifiques du tgf bêta |
EP3954704A1 (fr) | 2011-06-03 | 2022-02-16 | XOMA Technology Ltd. | Anticorps spécifiques du tgf bêta |
US11357217B2 (en) | 2011-08-05 | 2022-06-14 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
US10130081B2 (en) | 2011-08-05 | 2018-11-20 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
WO2013040142A2 (fr) | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Procédés bio-informatiques de détermination de liaisons peptidiques |
US11051497B2 (en) | 2011-09-19 | 2021-07-06 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9963716B2 (en) | 2011-09-26 | 2018-05-08 | Kymab Limited | Chimaeric surrogate light chains (SLC) comprising human VpreB |
US11261248B2 (en) | 2011-10-17 | 2022-03-01 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
US10246509B2 (en) | 2011-10-17 | 2019-04-02 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
US9932398B2 (en) | 2011-10-17 | 2018-04-03 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
WO2013096516A1 (fr) | 2011-12-19 | 2013-06-27 | Xoma Technology Ltd. | Méthodes de traitement de l'acné |
EP3050900A1 (fr) | 2011-12-19 | 2016-08-03 | Xoma (Us) Llc | Procédés pour le traitement de l'acnée |
US9706759B2 (en) | 2011-12-20 | 2017-07-18 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
US10561124B2 (en) | 2011-12-20 | 2020-02-18 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
US9622459B2 (en) | 2011-12-20 | 2017-04-18 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
US11617357B2 (en) | 2011-12-20 | 2023-04-04 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
US11612151B2 (en) | 2011-12-20 | 2023-03-28 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
WO2013102149A1 (fr) | 2011-12-31 | 2013-07-04 | Abbott Laboratories | Protéine de liaison de la vitamine d humaine tronquée et mutation et fusion de celle-ci, et matériaux associés et procédés d'utilisation |
WO2013117735A1 (fr) | 2012-02-09 | 2013-08-15 | Medical Research Council | Conjugué comprenant un agent et un ligand antiviral, et son utilisation dans un procédé d'administration de l'agent par voie intracellulaire |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
US9938358B2 (en) | 2012-03-28 | 2018-04-10 | Kymab Limited | Animal models and therapeutic molecules |
US9924705B2 (en) | 2012-03-28 | 2018-03-27 | Kymab Limited | Animal models and therapeutic molecules |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US9938357B2 (en) | 2012-03-28 | 2018-04-10 | Kymab Limited | Animal models and therapeutic molecules |
US9896516B2 (en) | 2012-03-28 | 2018-02-20 | Kymab Limited | Animal models and therapeutic molecules |
US11297811B2 (en) | 2012-03-28 | 2022-04-12 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US10774155B2 (en) | 2012-03-28 | 2020-09-15 | Kymab Limited | Animal models and therapeutic molecules |
WO2013144567A1 (fr) | 2012-03-28 | 2013-10-03 | Kymab Limited | Vertébré non-humain transgénique pour l'expression d'anticorps entièrement humains à commutation isotypique |
EP2831245A1 (fr) * | 2012-03-28 | 2015-02-04 | Kymab Limited | Vertébré non-humain transgénique pour l'expression d'anticorps entièrement humains à commutation isotypique |
US9758805B2 (en) | 2012-04-20 | 2017-09-12 | Merus N.V. | Methods and means for the production of Ig-like molecules |
US11926859B2 (en) | 2012-04-20 | 2024-03-12 | Merus N.V. | Methods and means for the production of Ig-like molecules |
US10337045B2 (en) | 2012-04-20 | 2019-07-02 | Merus N.V. | Methods and means for the production of Ig-like molecules |
US10329596B2 (en) | 2012-04-20 | 2019-06-25 | Merus N.V. | Methods and means for the production of Ig-like molecules |
US10752929B2 (en) | 2012-04-20 | 2020-08-25 | Merus N.V. | Methods and means for the production of ig-like molecules |
US10667501B2 (en) | 2012-05-17 | 2020-06-02 | Kymab Limited | Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins |
US10238093B2 (en) | 2012-06-12 | 2019-03-26 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
US10542735B2 (en) | 2012-06-12 | 2020-01-28 | Regerneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
US11559050B2 (en) | 2012-06-12 | 2023-01-24 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
US11666040B2 (en) | 2012-06-12 | 2023-06-06 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
WO2014058875A2 (fr) | 2012-10-09 | 2014-04-17 | Biogen Idec Ma Inc. | Polythérapies et leurs utilisations pour le traitement de troubles de la démyélinisation |
EP3750560A2 (fr) | 2012-10-09 | 2020-12-16 | Biogen MA Inc. | Polythérapies et utilisations pour le traitement de troubles de démyélinisation |
US9930871B2 (en) | 2013-02-20 | 2018-04-03 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
US10226033B2 (en) | 2013-03-18 | 2019-03-12 | Kymab Limited | Animal models and therapeutic molecules |
US11297810B2 (en) | 2013-03-18 | 2022-04-12 | Kymab Limited | Animal models and therapeutic molecules |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US11820810B2 (en) | 2013-05-02 | 2023-11-21 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US10730930B2 (en) | 2013-05-02 | 2020-08-04 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US10149462B2 (en) | 2013-10-01 | 2018-12-11 | Kymab Limited | Animal models and therapeutic molecules |
US11399522B2 (en) | 2013-10-01 | 2022-08-02 | Kymab Limited | Animal models and therapeutic molecules |
EP3514179A1 (fr) | 2014-01-24 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | Molécules d'anticorps anti-pd-1 et leurs utilisations |
EP4324518A2 (fr) | 2014-01-31 | 2024-02-21 | Novartis AG | Molécules d'anticorps anti-tim-3 et leurs utilisations |
EP4047015A1 (fr) | 2014-02-11 | 2022-08-24 | Visterra, Inc. | Molécules d'anticorps contre le virus de la dengue et leurs utilisations |
WO2015122995A1 (fr) | 2014-02-11 | 2015-08-20 | Visterra, Inc. | Molécules d'anticorps se liant au virus de la dengue et leurs utilisations |
EP3660050A1 (fr) | 2014-03-14 | 2020-06-03 | Novartis AG | Molécules d'anticorps anti-lag-3 et leurs utilisations |
WO2015138920A1 (fr) | 2014-03-14 | 2015-09-17 | Novartis Ag | Molécules d'anticorps anti-lag-3 et leurs utilisations |
US10881085B2 (en) | 2014-03-21 | 2021-01-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
US10787522B2 (en) | 2014-03-21 | 2020-09-29 | Regeneron Pharmaceuticals, Inc. | VL antigen binding proteins exhibiting distinct binding characteristics |
EP3659621A1 (fr) | 2014-09-13 | 2020-06-03 | Novartis AG | Polythérapies contre le cancer |
WO2016040880A1 (fr) | 2014-09-13 | 2016-03-17 | Novartis Ag | Thérapies combinées d'inhibiteurs d'alk |
WO2016040892A1 (fr) | 2014-09-13 | 2016-03-17 | Novartis Ag | Polythérapies |
EP3925622A1 (fr) | 2014-09-13 | 2021-12-22 | Novartis AG | Polythérapies |
WO2016054555A2 (fr) | 2014-10-03 | 2016-04-07 | Novartis Ag | Polythérapies |
EP3662903A2 (fr) | 2014-10-03 | 2020-06-10 | Novartis AG | Polythérapies |
WO2016061142A1 (fr) | 2014-10-14 | 2016-04-21 | Novartis Ag | Molécules d'anticorps de pd-l1 et leurs utilisations |
EP4245376A2 (fr) | 2014-10-14 | 2023-09-20 | Novartis AG | Molécules d'anticorps de pd-l1 et leurs utilisations |
WO2016100882A1 (fr) | 2014-12-19 | 2016-06-23 | Novartis Ag | Polythérapies |
US10435467B2 (en) | 2015-01-08 | 2019-10-08 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
WO2016141111A1 (fr) | 2015-03-03 | 2016-09-09 | Xoma (Us) Llc | Traitement d'une hyperinsulinémie post-prandiale et d'une hypoglycémie après chirurgie bariatrique |
US10711067B2 (en) | 2015-03-03 | 2020-07-14 | Xoma (Us) Llc | Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery |
US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
WO2016161410A2 (fr) | 2015-04-03 | 2016-10-06 | Xoma Technology Ltd. | Traitement du cancer à l'aide d'inhibiteurs de tgf-bêta et pd-1 |
US10167334B2 (en) | 2015-04-03 | 2019-01-01 | Xoma Technology Ltd. | Treatment of cancer using anti-TGF-BETA and PD-1 antibodies |
US11685775B2 (en) | 2015-04-03 | 2023-06-27 | Xoma Technology Ltd. | Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody |
US10683347B2 (en) | 2015-04-03 | 2020-06-16 | Xoma Technology Ltd. | Treatment of cancer using anti-TGF-β and anti-PD-1 antibodies |
EP3770171A1 (fr) | 2015-04-03 | 2021-01-27 | XOMA Technology Ltd. | Traitement du cancer à l'aide d'inhibiteurs de tgf-bêta et pd-1 |
EP3964528A1 (fr) | 2015-07-29 | 2022-03-09 | Novartis AG | Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3 |
WO2017019897A1 (fr) | 2015-07-29 | 2017-02-02 | Novartis Ag | Polythérapies comprenant des molécules d'anticorps contre tim -3 |
EP3878465A1 (fr) | 2015-07-29 | 2021-09-15 | Novartis AG | Polythérapies comprenant des molécules d'anticorps tim-3 |
WO2017019894A1 (fr) | 2015-07-29 | 2017-02-02 | Novartis Ag | Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3 |
US10253101B2 (en) | 2015-08-06 | 2019-04-09 | Xoma (Us) Llc | Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia |
WO2017083515A2 (fr) | 2015-11-10 | 2017-05-18 | Visterra, Inc. | Conjugués molécules anticorps-médicaments et leurs utilisations |
WO2017091683A1 (fr) | 2015-11-25 | 2017-06-01 | Visterra, Inc. | Molécules d'anticorps se liant à april et leurs utilisations |
EP4285923A2 (fr) | 2015-11-25 | 2023-12-06 | Visterra, Inc. | Molécules d'anticorps se liant à april et leurs utilisations |
WO2017106810A2 (fr) | 2015-12-17 | 2017-06-22 | Novartis Ag | Combinaison d'un inhibiteur de c-met avec une molécule d'anticorps dirigée contre pd-1 et ses utilisations |
WO2017106656A1 (fr) | 2015-12-17 | 2017-06-22 | Novartis Ag | Molécules d'anticorps anti-pd-1 et leurs utilisations |
US11725247B2 (en) | 2016-02-29 | 2023-08-15 | Foundation Medicine, Inc. | Methods of treating cancer |
WO2017158426A1 (fr) | 2016-03-14 | 2017-09-21 | University Of Oslo | Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée |
WO2017158421A1 (fr) | 2016-03-14 | 2017-09-21 | University Of Oslo | Immunoglobulines anti-virales synthétiques |
WO2017158436A1 (fr) | 2016-03-17 | 2017-09-21 | Oslo Universitetssykehus Hf | Protéines de fusion ciblant des macrophages associés aux tumeurs pour le traitement du cancer |
WO2017165464A1 (fr) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Molécules multispécifiques et multifonctionnelles et leurs utilisations |
WO2017165736A1 (fr) | 2016-03-25 | 2017-09-28 | Visterra, Inc. | Formulations de molécules d'anticorps contre le virus de la dengue |
WO2017181098A2 (fr) | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Molécules d'anticorps se liant au virus zika et leurs utilisations |
WO2017221072A2 (fr) | 2016-06-21 | 2017-12-28 | University Of Oslo | Fragments de vaccin de liaison à hla et leurs utilisations |
US11780924B2 (en) | 2016-06-21 | 2023-10-10 | University Of Oslo | HLA binding vaccine moieties and uses thereof |
WO2018013714A1 (fr) | 2016-07-13 | 2018-01-18 | Biogen Ma Inc. | Schémas posologiques d'antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation |
US11787876B2 (en) | 2016-08-01 | 2023-10-17 | Xoma (Us) Llc | Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof |
WO2018026748A1 (fr) | 2016-08-01 | 2018-02-08 | Xoma (Us) Llc | Anticorps du récepteur 1 de l'hormone de parathyroïde (pth1r) et leurs utilisations |
US10519250B2 (en) | 2016-08-01 | 2019-12-31 | Xoma (Us) Llc | Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof |
WO2018052556A1 (fr) | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Polypeptides synthétiques et leurs utilisations |
WO2018057955A1 (fr) | 2016-09-23 | 2018-03-29 | Elstar Therapeutics, Inc. | Molécules d'anticorps multispécifiques comprenant des chaînes légères lambda et kappa |
US11673971B2 (en) | 2016-09-23 | 2023-06-13 | Marengo Therapeutics, Inc. | Multispecific antibody molecules comprising lambda and kappa light chains |
WO2018064255A2 (fr) | 2016-09-28 | 2018-04-05 | Xoma (Us) Llc | Anticorps se liant à l'interleukin-2 et leurs utilisations |
US10858428B2 (en) | 2016-09-28 | 2020-12-08 | Xoma (Us) Llc | Antibodies that bind interleukin-2 and uses thereof |
WO2018119402A1 (fr) | 2016-12-23 | 2018-06-28 | Visterra, Inc. | Polypeptides de liaison et leurs procédés de production |
WO2018136626A1 (fr) | 2017-01-18 | 2018-07-26 | Visterra, Inc. | Conjugués molécule d'anticorps-médicament et leurs utilisations |
WO2018151820A1 (fr) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles comprenant un ligand trimérique et leurs utilisations |
WO2018158719A1 (fr) | 2017-03-02 | 2018-09-07 | Novartis Ag | Protéines hétérodimères modifiées |
US11179377B2 (en) | 2017-03-10 | 2021-11-23 | Embera Neurotherapeutics, Inc. | Pharmaceutical compositions and uses thereof |
US11571459B2 (en) | 2017-04-03 | 2023-02-07 | Oncxerna Therapeutics, Inc. | Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents |
WO2018187227A1 (fr) | 2017-04-03 | 2018-10-11 | Concologie, Inc. | Procédés de traitement du cancer à l'aide d'anticorps ciblant ps avec des agents immuno-oncologiques |
WO2018195283A1 (fr) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Molécules multispécifiques et utilisations correspondantes |
EP4328241A2 (fr) | 2017-04-28 | 2024-02-28 | Marengo Therapeutics, Inc. | Molécules multispécifiques comprenant un domaine d'hétérodimère non-immunoglobuline et leurs utilisations |
WO2018201051A1 (fr) | 2017-04-28 | 2018-11-01 | Novartis Ag | Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase |
WO2018201047A1 (fr) | 2017-04-28 | 2018-11-01 | Elstar Therapeutics, Inc. | Molécules multispécifiques comprenant un domaine d'hétérodimérisation non immunoglobuline et leurs utilisations |
WO2018222901A1 (fr) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à une protéine de leucémie myéloproliférative (mpl) et leurs utilisations |
WO2018237173A1 (fr) | 2017-06-22 | 2018-12-27 | Novartis Ag | Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes |
WO2018237157A1 (fr) | 2017-06-22 | 2018-12-27 | Novartis Ag | Molécules d'anticorps se liant à cd73 et leurs utilisations |
WO2019006007A1 (fr) | 2017-06-27 | 2019-01-03 | Novartis Ag | Régimes posologiques pour anticorps anti-tim3 et leurs utilisations |
WO2019016213A1 (fr) | 2017-07-19 | 2019-01-24 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | ANTICORPS β (Aβ) AMYLOÏDES ANTI-ISOASP7 ET LEURS UTILISATIONS |
EP3431496A1 (fr) | 2017-07-19 | 2019-01-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anticorps amyloïdes beta anti-isoasp7 et leurs utilisations |
US11703511B2 (en) | 2017-07-19 | 2023-07-18 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-isoAsp7 amyloid β (Aβ) antibodies and uses thereof |
WO2019018730A1 (fr) | 2017-07-20 | 2019-01-24 | Novartis Ag | Régimes posologiques pour des anticorps anti-lag3 et leurs utilisations |
WO2019035938A1 (fr) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à bcma et leurs utilisations |
WO2019068733A1 (fr) | 2017-10-02 | 2019-04-11 | Certest Biotec, S.L. | Anticorps et dispositifs de test pour la détection de bactéries du genre campylobacter |
EP3461841A1 (fr) | 2017-10-02 | 2019-04-03 | Certest Biotec, S.L. | Anticorps et dispositifs d'essai pour la détection de bactéries du genre campylobacter |
WO2019070726A1 (fr) | 2017-10-02 | 2019-04-11 | Visterra, Inc. | Molécules d'anticorps se liant à cd73 et leurs utilisations |
US11945868B2 (en) | 2017-10-02 | 2024-04-02 | Visterra, Inc. | Antibody molecules to CD138 and uses thereof |
WO2019077132A1 (fr) | 2017-10-19 | 2019-04-25 | Debiopharm International S.A. | Produit de combinaison pour le traitement du cancer |
WO2019099838A1 (fr) | 2017-11-16 | 2019-05-23 | Novartis Ag | Polythérapies |
WO2019113464A1 (fr) | 2017-12-08 | 2019-06-13 | Elstar Therapeutics, Inc. | Molécules multispécifiques et utilisations correspondantes |
WO2019129137A1 (fr) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anticorps anti-lag-3 et utilisations associées |
WO2019129136A1 (fr) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | Anticorps anti-pd-l1 et ses applications |
US11512131B2 (en) | 2017-12-27 | 2022-11-29 | Innovent Biologies (Suzhou) Co., Ltd. | Anti-PD-L1 antibody and uses thereof |
US11572405B2 (en) | 2018-01-12 | 2023-02-07 | Bristol-Myers Squibb Company | Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer |
WO2019178362A1 (fr) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles se liant à calréticuline et utilisations associees |
WO2019178364A2 (fr) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles et utilisations associées |
WO2019200229A1 (fr) | 2018-04-13 | 2019-10-17 | Novartis Ag | Régimes posologiques pour anticorps anti-pd-l1 et utilisations associées |
WO2019232244A2 (fr) | 2018-05-31 | 2019-12-05 | Novartis Ag | Molécules d'anticorps anti-cd73 et leurs utilisations |
WO2019246293A2 (fr) | 2018-06-19 | 2019-12-26 | Atarga, Llc | Molécules d'anticorps se liant au composant du complément 5 et leurs utilisations |
US11965025B2 (en) | 2018-07-03 | 2024-04-23 | Marengo Therapeutics, Inc. | Method of treating solid cancers with bispecific interleukin-anti-TCRß molecules |
DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
WO2020010250A2 (fr) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Molécules d'anticorps anti-tcr et leurs utilisations |
US11845797B2 (en) | 2018-07-03 | 2023-12-19 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
WO2020021465A1 (fr) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Procédé de traitement de tumeurs neuroendocrines |
WO2020069372A1 (fr) | 2018-09-27 | 2020-04-02 | Elstar Therapeutics, Inc. | Molécules multispécifiques csf1r/ccr2 |
WO2020128898A1 (fr) | 2018-12-20 | 2020-06-25 | Novartis Ag | Combinaisons pharmaceutiques |
WO2020165868A1 (fr) | 2019-02-15 | 2020-08-20 | Perkinelmer Cellular Technologies Germany Gmbh | Pré-balayage d'objectif de microscope à faible puissance et balayage d'objectif de microscope à haute puissance dans une direction x, y et z pour imager des objets tels que des cellules à l'aide d'un microscope |
WO2020172605A1 (fr) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Molécules d'anticorps se liant à nkp30 et utilisations associees |
WO2020172601A1 (fr) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles se liant à la calréticuline et utilisations associées |
WO2020172571A1 (fr) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles se liant à des cellules cancéreuses associées à des lymphocytes t et leurs utilisations |
WO2020172598A1 (fr) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Molécules multifonctionnelles se liant à des lymphocytes t et leurs utilisations pour traiter des troubles auto-immuns |
WO2020172596A1 (fr) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Molécules d'anticorps anti-tcr et leurs utilisations |
WO2020205523A1 (fr) | 2019-03-29 | 2020-10-08 | Atarga, Llc | Anticorps anti-fgf23 |
WO2020257289A2 (fr) | 2019-06-17 | 2020-12-24 | Visterra, Inc. | Molécules d'anticorps humanisés se liant à cd138 et leurs utilisations |
WO2021021606A1 (fr) | 2019-07-26 | 2021-02-04 | Visterra, Inc. | Agents d'interleukine 2 et utilisations de ceux-ci |
WO2021079188A1 (fr) | 2019-10-21 | 2021-04-29 | Novartis Ag | Polythérapies comprenant du vénétoclax et des inhibiteurs de tim-3 |
WO2021079195A1 (fr) | 2019-10-21 | 2021-04-29 | Novartis Ag | Inhibiteurs de tim-3 et leurs utilisations |
WO2021123902A1 (fr) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combinaison d'anticorps anti-tim-3 mbg453 et d'anticorps anti-tgf-bêta nis793, avec ou sans décitabine ou l'anticorps anti pd-1 spartalizumab, pour le traitement de la myélofibrose et du syndrome myélodysplasique |
WO2021123996A1 (fr) | 2019-12-20 | 2021-06-24 | Novartis Ag | Utilisations d'anticorps anti-tgf-bêtas et inhibiteurs de point de contrôle pour le traitement des maladies prolifératives |
WO2021138407A2 (fr) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Molécules multifonctionnelles se liant à cd33 et utilisations associées |
WO2021146320A1 (fr) | 2020-01-13 | 2021-07-22 | Visterra, Inc. | Molécules d'anticorps anti-c5ar1 et leurs utilisations |
WO2021144657A1 (fr) | 2020-01-17 | 2021-07-22 | Novartis Ag | Polythérapies comprenant un inhibiteur tim-3 et un agent d'hypométhylation à utiliser dans le traitement du syndrome myélodysplasique ou de la leucémie myélomonocytaire chronique |
WO2021203024A1 (fr) | 2020-04-03 | 2021-10-07 | Visterra, Inc. | Conjugués molécule d'anticorps-médicament et leurs utilisations |
WO2021217085A1 (fr) | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Molécules multifonctionnelles se liant à des cellules cancéreuses associées à des lymphocytes t et leurs utilisations |
WO2021220215A1 (fr) | 2020-05-01 | 2021-11-04 | Novartis Ag | Immunoglobulines modifiées |
WO2021220218A1 (fr) | 2020-05-01 | 2021-11-04 | Novartis Ag | Variants d'immunoglobuline |
WO2021262999A1 (fr) | 2020-06-24 | 2021-12-30 | Visterra, Inc. | Molécules d'anticorps contre april et leurs utilisations |
WO2022026592A2 (fr) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Molécules d'anticorps contre le coronavirus et leurs utilisations |
WO2022046922A2 (fr) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Molécules d'anticorps se liant à nkp30 et utilisations associees |
WO2022046920A2 (fr) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Molécules multifonctionnelles se liant à la calréticuline et utilisations associées |
WO2022047046A1 (fr) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Procédés de détection de trbc1 ou de trbc2 |
WO2022043558A1 (fr) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Méthode de traitement de cancers exprimant le psma |
WO2022043557A1 (fr) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Méthode de traitement de cancers exprimant le psma |
WO2022120224A1 (fr) | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Procédés d'utilisation d'agents d'interleukine-2 |
WO2022159590A1 (fr) | 2021-01-20 | 2022-07-28 | Visterra, Inc. | Mutants d'interleukine-2 et leurs utilisations |
WO2022162569A1 (fr) | 2021-01-29 | 2022-08-04 | Novartis Ag | Régimes posologiques d'anticorps anti-cd73 et anti-entpd2 et leurs utilisations |
WO2022182872A2 (fr) | 2021-02-24 | 2022-09-01 | Alladapt Immunotherapeutics, Inc. | Compositions et méthodes pour l'identification de protéines allergènes à réactivité croisée et traitement d'allergies |
WO2022195551A1 (fr) | 2021-03-18 | 2022-09-22 | Novartis Ag | Biomarqueurs pour le cancer et leurs méthodes d'utilisation |
WO2022215011A1 (fr) | 2021-04-07 | 2022-10-13 | Novartis Ag | UTILISATIONS D'ANTICORPS ANTI-TGFβ ET D'AUTRES AGENTS THÉRAPEUTIQUES POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES |
WO2022216993A2 (fr) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Molécules multifonctionnelles se liant au tcr et leurs utilisations |
WO2023044483A2 (fr) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions et procédés pour le traitement du cancer positif her2 |
WO2023092004A1 (fr) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions et méthodes pour le traitement de troubles liés à tau |
WO2023097254A1 (fr) | 2021-11-24 | 2023-06-01 | Visterra, Inc. | Molécules modifiées d'anticorps anti-cd138 et leurs utilisations |
WO2023102463A1 (fr) | 2021-12-01 | 2023-06-08 | Visterra, Inc. | Procédés d'utilisation d'agents d'interleukine-2 |
WO2023139292A1 (fr) | 2022-01-24 | 2023-07-27 | Cambridge Enterprise Limited | Thérapie anti-tau |
WO2023150778A1 (fr) | 2022-02-07 | 2023-08-10 | Visterra, Inc. | Molécules d'anticorps anti-idiotype et leurs utilisations |
WO2023212518A1 (fr) | 2022-04-25 | 2023-11-02 | Visterra, Inc. | Molécules d'anticorps contre april et leurs utilisations |
WO2023220695A2 (fr) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions et procédés pour le traitement du cancer her2 positif |
WO2023247312A1 (fr) | 2022-06-23 | 2023-12-28 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Protéines de liaison anti-transthyrétine (ttr) et leurs utilisations |
EP4296279A1 (fr) | 2022-06-23 | 2023-12-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Protéines de liaison anti-transthyrétine (ttr) et leurs utilisations |
WO2024030976A2 (fr) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions et procédés permettant le franchissement de la barrière hémato-encéphalique |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991000906A1 (fr) | Animaux chimeriques et transgeniques pouvant produire des anticorps humains | |
EP0710719B1 (fr) | Génération d'anticorps xénogeniques | |
JP2938569B2 (ja) | 異種免疫グロブリンを作る方法及びトランスジェニックマウス | |
KR100891634B1 (ko) | 비동족형 스위치 영역에 의해 인간 항체의 특정 이소타입을생산하는 트랜스제닉 동물 | |
CA2124967C (fr) | Animaux transgeniques non humains capables de produire des anticorps heterologues | |
JP5588866B2 (ja) | Hco32およびhco27、ならびに関連実施例 | |
RU2559524C2 (ru) | Продуцирующие антитела млекопитающие, не являющиеся человеком | |
JP2001527386A (ja) | 異種抗体を産生し得るトランスジェニック非ヒト動物 | |
CN104994729A (zh) | 编码具有人独特型的啮齿动物抗体的多核苷酸以及包含所述多核苷酸的动物 | |
CN101002549A (zh) | 能够生产异源抗体的转基因非人动物 | |
AU2011271046A1 (en) | Hybrid light chain mice | |
CN112715482A (zh) | 表达人源化抗体的非人转基因动物及其用途 | |
JPH11206387A (ja) | 異種免疫グロブリンを作る方法及びそのためのトランスジェニックマウス | |
AU720612B2 (en) | Transgenic non-human animals capable of producing heterologous antibodies | |
NZ749259B2 (en) | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
NENP | Non-entry into the national phase |
Ref country code: CA |